Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA single cell type specificity" "RNA single cell type distribution" "RNA single cell type specificity score" "RNA single cell type specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "CCD Protein" "CCD Transcript" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - GAMG [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - hTERT-RPE1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - JURKAT [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - OE19 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - SuSa [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" "Single Cell Type RNA - Alveolar cells type 1 [NX]" "Single Cell Type RNA - Alveolar cells type 2 [NX]" "Single Cell Type RNA - B-cells [NX]" "Single Cell Type RNA - Basal glandular cells [NX]" "Single Cell Type RNA - Basal keratinocytes [NX]" "Single Cell Type RNA - Bipolar cells [NX]" "Single Cell Type RNA - Cardiomyocytes [NX]" "Single Cell Type RNA - Cholangiocytes [NX]" "Single Cell Type RNA - Ciliated cells [NX]" "Single Cell Type RNA - Club cells [NX]" "Single Cell Type RNA - Collecting duct cells [NX]" "Single Cell Type RNA - Cone photoreceptor cells [NX]" "Single Cell Type RNA - Cytotrophoblasts [NX]" "Single Cell Type RNA - Distal tubular cells [NX]" "Single Cell Type RNA - Ductal cells [NX]" "Single Cell Type RNA - Early spermatids [NX]" "Single Cell Type RNA - Endothelial cells [NX]" "Single Cell Type RNA - Enterocytes [NX]" "Single Cell Type RNA - Erythroid cells [NX]" "Single Cell Type RNA - Exocrine glandular cells [NX]" "Single Cell Type RNA - Extravillous trophoblasts [NX]" "Single Cell Type RNA - Fibroblasts [NX]" "Single Cell Type RNA - Glandular cells [NX]" "Single Cell Type RNA - granulocytes [NX]" "Single Cell Type RNA - Hepatocytes [NX]" "Single Cell Type RNA - Hofbauer cells [NX]" "Single Cell Type RNA - Horizontal cells [NX]" "Single Cell Type RNA - Intestinal endocrine cells [NX]" "Single Cell Type RNA - Ito cells [NX]" "Single Cell Type RNA - Kupffer cells [NX]" "Single Cell Type RNA - Late spermatids [NX]" "Single Cell Type RNA - Leydig cells [NX]" "Single Cell Type RNA - Macrophages [NX]" "Single Cell Type RNA - Melanocytes [NX]" "Single Cell Type RNA - monocytes [NX]" "Single Cell Type RNA - Mucus-secreting cells [NX]" "Single Cell Type RNA - Muller glia cells [NX]" "Single Cell Type RNA - Pancreatic endocrine cells [NX]" "Single Cell Type RNA - Paneth cells [NX]" "Single Cell Type RNA - Peritubular cells [NX]" "Single Cell Type RNA - Proximal tubular cells [NX]" "Single Cell Type RNA - Rod photoreceptor cells [NX]" "Single Cell Type RNA - Sertoli cells [NX]" "Single Cell Type RNA - Smooth muscle cells [NX]" "Single Cell Type RNA - Spermatocytes [NX]" "Single Cell Type RNA - Spermatogonia [NX]" "Single Cell Type RNA - Suprabasal keratinocytes [NX]" "Single Cell Type RNA - Syncytiotrophoblasts [NX]" "Single Cell Type RNA - T-cells [NX]" "Single Cell Type RNA - Undifferentiated cells [NX]" "Single Cell Type RNA - Urothelial cells [NX]" ADORA2A "ADORA2, RDC8" ENSG00000128271 "Adenosine A2a receptor" P29274 22 24417879-24442360 "Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "G-protein coupled receptor, Receptor, Transducer" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 7 "blood: 22.8;bone marrow: 28.1;brain: 43.9;lymphoid tissue: 59.0" "Cell type enriched" "Detected in single" 25 "monocytes: 19.0" "Not detected" "Not detected" "Region enriched" "Detected in all" 8 "basal ganglia: 43.9" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Daudi: 15.4;Karpas-707: 21.2;RPMI-8226: 15.0;SK-BR-3: 30.4;U-266/70: 21.2;U-266/84: 27.7;U-698: 21.7" "Region enriched" "Detected in some" 10 "basal ganglia: 357.5" "Region enriched" "Detected in single" 92 "basal ganglia: 166.0" "CAB001943, HPA065566, HPA075997" Enhanced Supported NA NA "CAB001943: , HPA065566: , HPA075997: AB_2732298" "unprognostic (7.30e-2)" "unprognostic (2.42e-2)" "unprognostic (3.30e-2)" "unprognostic (2.04e-1)" "unprognostic (7.44e-2)" "unprognostic (1.88e-3)" "unprognostic (9.85e-2)" "unprognostic (3.63e-1)" "unprognostic (2.88e-2)" "unprognostic (4.57e-3)" "unprognostic (2.15e-3)" "unprognostic (1.87e-3)" "unprognostic (6.81e-4)" "unprognostic (1.50e-1)" "unprognostic (9.78e-3)" "unprognostic (1.30e-1)" "unprognostic (7.10e-3)" 1.0 2.4 1.9 10.4 43.9 28.1 1.5 3.4 3.8 0.8 2.0 1.7 0.3 5.4 1.4 1.4 1.0 0.9 2.4 3.5 2.4 1.8 3.5 4.3 5.1 14.8 2.6 1.6 1.2 0.8 0.0 2.1 1.4 2.3 1.6 0.8 3.3 2.7 1.5 1.2 0.9 2.6 0.7 1.3 7.5 2.8 2.0 5.7 59.0 1.3 0.9 8.6 3.8 1.3 17.7 1.1 13.7 9.0 2.2 22.8 11.2 0.2 0.3 0.4 0.1 0.2 0.1 0.4 0.2 9.5 0.5 1.0 1.7 0.1 15.4 1.0 0.3 1.0 0.3 0.9 0.0 0.0 1.8 2.7 0.2 0.0 2.2 0.2 0.3 7.7 0.1 0.0 2.9 0.0 0.2 3.4 2.2 0.1 21.2 0.0 0.2 5.3 1.6 0.6 2.0 0.0 0.2 0.7 15.0 0.0 0.1 1.5 8.9 0.4 30.4 0.1 0.4 0.4 1.5 0.2 0.9 1.5 0.2 0.1 21.2 27.7 21.7 4.8 5.2 0.1 3.0 0.8 4.8 8.6 2.6 20.1 9.6 16.1 16.9 1.1 17.7 22.8 18.3 13.7 2.2 9.0 1.1 21.4 11.2 1.9 43.9 3.4 3.8 2.4 1.8 2.6 1.6 2.3 5.7 0.0 0.3 0.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ADRB3 ENSG00000188778 "Adrenoceptor beta 3" P13945 8 37962991-37966965 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Diabetes mellitus, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "gallbladder: 23.9;ovary: 15.7;smooth muscle: 10.8" "Not detected" "Not detected" "Not detected" "Not detected" "Region enhanced" "Detected in single" "amygdala: 1.3" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "HeLa: 2.4;Karpas-707: 1.0;U-2 OS: 1.3" "Low region specificity" "Detected in some" "Not detected" "Not detected" HPA061969 Uncertain NA NA "HPA061969: AB_2732674" "unprognostic (1.70e-1)" "unprognostic (2.24e-1)" "unprognostic (6.64e-3)" "unprognostic (5.41e-1)" "unprognostic (1.07e-2)" "unprognostic (1.07e-1)" "unprognostic (1.14e-1)" "unprognostic (9.49e-2)" "unprognostic (2.33e-1)" "unprognostic (1.06e-3)" "unprognostic (3.77e-2)" "unprognostic (2.29e-8)" "unprognostic (1.10e-3)" "unprognostic (2.81e-2)" "unprognostic (5.37e-2)" "unprognostic (6.06e-3)" 0.4 0.1 1.3 1.9 0.3 0.3 0.3 0.0 0.8 1.6 2.3 0.0 0.0 0.4 0.9 1.9 1.7 5.3 23.9 0.1 0.2 0.1 0.1 0.0 0.2 1.2 0.0 0.0 15.7 0.0 0.0 0.0 4.7 0.0 4.1 0.4 0.0 0.0 0.1 0.0 0.1 0.9 10.8 0.0 0.0 3.0 0.2 0.0 0.0 0.0 0.0 0.1 9.9 1.5 0.9 0.2 1.2 0.4 0.8 0.5 0.0 0.2 0.2 0.1 0.1 0.3 0.7 0.0 0.1 0.0 0.1 0.0 0.0 0.6 0.3 0.0 0.3 0.0 0.0 0.3 0.0 0.1 0.1 0.0 0.0 2.4 0.4 0.8 0.0 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.3 0.2 1.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.3 0.3 0.0 0.0 0.2 0.1 0.4 0.4 0.4 1.3 0.1 0.0 0.2 0.1 0.1 0.2 0.1 0.0 1.0 0.3 0.3 0.1 0.1 0.4 0.7 0.2 0.1 0.0 0.9 0.2 0.2 1.2 0.8 0.4 0.2 0.5 0.0 1.3 0.3 0.0 0.8 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 C7orf57 ENSG00000164746 "Chromosome 7 open reading frame 57" Q8NEG2 7 48035511-48061304 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 20.0;fallopian tube: 20.9;testis: 11.4" "Cell type enriched" "Detected in some" 6 "Ciliated cells: 143.2" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in many" "pons and medulla: 20.0" "Cell type enhanced" "Detected in single" "MAIT T-cell: 2.3" "Lineage enhanced" "Detected in single" "T-cells: 2.3" "Cell line enhanced" "Detected in some" "GAMG: 6.2;hTERT-HME1: 9.8;U-266/70: 5.8;U-698: 3.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA021286 Enhanced NA NA "HPA021286: AB_1845760" "unprognostic (1.74e-2)" "unprognostic (4.82e-2)" "unprognostic (3.13e-2)" "unprognostic (1.28e-2)" "unprognostic (2.77e-3)" "unprognostic (3.22e-2)" "unprognostic (1.21e-2)" "unprognostic (1.32e-1)" "unprognostic (3.29e-1)" "unprognostic (1.37e-1)" "unprognostic (4.98e-2)" "unprognostic (2.88e-1)" "unprognostic (3.93e-5)" "unprognostic (5.17e-3)" "unprognostic (6.18e-2)" "unprognostic (3.42e-3)" "unprognostic (1.20e-1)" 0.2 0.2 2.3 0.2 5.0 0.5 0.3 0.1 1.0 0.8 0.2 3.5 0.0 0.3 0.9 7.1 1.4 20.9 0.2 0.3 3.7 4.0 0.3 0.2 4.3 0.3 0.1 0.4 1.6 0.1 0.7 0.4 0.2 20.0 0.2 0.2 0.0 0.2 0.2 0.2 0.3 0.2 0.2 0.7 0.2 0.2 11.4 2.1 0.0 0.5 1.8 0.4 0.2 0.5 0.0 0.1 0.0 0.0 0.6 2.3 0.1 0.7 0.2 0.1 0.1 0.0 0.0 0.2 0.1 0.5 0.3 0.4 0.0 2.4 0.0 0.2 0.1 6.2 0.3 0.0 1.0 0.7 0.0 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 9.8 0.1 0.0 0.0 0.0 0.1 0.4 0.1 0.1 0.0 0.2 0.0 1.0 0.0 0.0 0.0 0.1 0.1 0.9 0.1 0.1 0.0 0.3 0.8 0.0 0.0 0.1 0.6 0.9 0.4 0.6 5.8 0.8 3.3 1.4 0.0 0.9 0.0 0.0 0.0 0.6 0.0 2.3 0.0 0.6 0.6 0.1 0.0 0.4 0.2 0.0 0.6 0.0 0.0 0.0 0.1 2.3 5.0 0.1 1.0 3.7 4.0 0.1 0.4 20.0 2.1 0.0 4.8 0.0 0.0 0.0 0.0 0.8 0.0 143.2 22.7 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.1 0.2 0.1 2.3 0.0 0.1 0.0 0.0 0.0 0.0 2.7 0.0 0.2 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.8 0.0 0.0 9.4 0.4 0.0 0.0 0.0 0.0 0.0 CACNG3 ENSG00000006116 "Calcium voltage-gated channel auxiliary subunit gamma 3" O60359 16 24255553-24362801 "Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Ion channel, Voltage-gated channel" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 18 "brain: 32.2" "Cell type enriched" "Detected in some" 46 "Horizontal cells: 166.8" "Cancer enriched" "Detected in single" 15 "glioma: 0.7" "Group enriched" "Detected in many" 6 "amygdala: 12.8;basal ganglia: 13.1;cerebral cortex: 20.0;hippocampal formation: 12.7" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "HeLa: 1.3;Karpas-707: 1.0;U-266/70: 1.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA077238 Enhanced NA NA "HPA077238: " "unprognostic (5.61e-2)" "unprognostic (3.09e-1)" "unprognostic (2.12e-1)" "unprognostic (1.17e-1)" 0.4 1.8 12.8 0.4 13.1 0.5 0.3 0.2 32.2 0.3 0.4 0.1 0.0 0.3 0.3 0.4 0.3 0.4 0.3 0.3 12.7 2.2 0.3 0.4 0.3 0.4 1.8 2.3 0.4 0.3 0.3 0.0 0.4 0.3 0.4 0.4 0.1 0.3 0.4 0.3 0.4 0.3 0.4 0.3 0.4 0.4 0.6 0.0 0.0 0.3 0.0 0.4 0.3 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 1.3 0.0 0.0 0.5 0.1 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.0 1.1 0.0 0.2 0.9 0.2 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 12.8 13.1 0.2 20.0 12.7 2.2 1.8 2.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 166.8 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 CALB1 CALB ENSG00000104327 "Calbindin 1" P05937 8 90058608-90095475 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 15 "brain: 73.8;kidney: 121.9" "Cell type enhanced" "Detected in some" 16 "Collecting duct cells: 26.2;Cone photoreceptor cells: 86.4;Distal tubular cells: 26.6;Horizontal cells: 93.8" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 6.4" "Group enriched" "Detected in many" 7 "granulocytes: 6.4;monocytes: 2.5" "Cell line enhanced" "Detected in many" "A-431: 39.3;EFO-21: 59.6;NTERA-2: 19.4;SuSa: 25.6" "Region enhanced" "Detected in many" "cerebellum: 483.1" "Group enriched" "Detected in all" 4 "basal ganglia: 88.7;cerebellum: 312.3" "CAB002138, HPA023099, HPA056734" Enhanced Approved Vesicles NA NA Vesicles "CAB002138: AB_563448, HPA023099: AB_1845859, HPA056734: AB_2683220" "unprognostic (2.19e-1)" "unprognostic (2.28e-3)" "unprognostic (2.61e-2)" "prognostic unfavorable (1.60e-4)" "unprognostic (1.82e-1)" "unprognostic (5.39e-2)" "unprognostic (2.05e-1)" "unprognostic (1.27e-1)" "unprognostic (3.49e-2)" "unprognostic (1.37e-2)" "unprognostic (7.36e-2)" "unprognostic (1.59e-1)" "unprognostic (9.01e-2)" "unprognostic (2.11e-1)" "unprognostic (7.88e-2)" "unprognostic (2.24e-1)" "unprognostic (1.42e-1)" 1.6 1.2 19.6 1.4 73.8 1.0 1.4 66.0 10.9 3.1 1.3 0.5 0.0 1.0 1.0 2.0 1.7 2.0 0.9 1.0 13.8 15.2 121.9 1.5 2.1 1.0 2.8 6.4 0.9 2.0 1.3 3.2 2.2 12.8 0.9 1.4 0.8 1.3 0.8 1.4 1.7 1.1 1.2 14.7 1.1 1.3 2.1 10.6 0.0 1.4 0.0 1.0 1.0 0.1 0.5 0.6 6.4 2.5 0.0 0.2 1.0 39.3 2.1 8.9 0.6 0.2 1.4 1.2 0.6 4.0 0.3 0.5 0.3 4.7 0.2 59.6 0.0 0.6 13.7 12.8 15.8 2.7 0.1 0.7 1.4 16.5 0.3 1.7 0.2 0.7 0.6 5.1 0.8 7.8 2.1 10.6 0.7 2.7 1.1 10.5 0.2 0.6 0.1 19.4 0.5 8.0 0.3 0.2 0.7 4.7 0.3 1.4 0.9 10.7 0.7 0.1 25.6 0.5 0.5 0.0 1.5 8.4 1.9 3.4 1.0 1.3 0.3 0.2 0.1 0.1 2.6 0.5 1.5 0.2 0.7 0.0 0.0 0.0 0.1 0.1 0.5 0.2 0.2 6.4 0.0 2.5 0.6 0.0 1.0 19.6 73.8 66.0 10.9 13.8 15.2 2.8 6.4 12.8 10.6 0.0 0.0 0.0 0.0 0.0 20.2 1.6 0.0 0.0 0.0 26.2 86.4 0.0 26.6 0.0 5.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 93.8 3.4 0.0 0.0 1.3 0.9 0.0 0.0 0.0 0.0 17.8 0.2 0.0 0.0 0.0 12.3 0.0 0.3 0.3 0.0 0.0 0.1 0.0 0.0 0.0 CALY "CALCYON, DRD1IP, NSG3" ENSG00000130643 "Calcyon neuron specific vesicular protein" Q9NYX4 10 133324072-133336935 "FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins" Endocytosis "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 9 "adrenal gland: 26.5;brain: 98.9;pituitary gland: 47.7" "Cell type enhanced" "Detected in some" 19 "Bipolar cells: 84.4;Horizontal cells: 68.3;Intestinal endocrine cells: 18.7;Rod photoreceptor cells: 31.1" "Group enriched" "Detected in some" 14 "glioma: 1.7;pancreatic cancer: 7.7" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory CD8 T-cell: 1.3;naive CD4 T-cell: 1.0" "Lineage enriched" "Detected in single" 14 "T-cells: 1.3" "Cell line enhanced" "Detected in some" "SH-SY5Y: 2.7;U-266/70: 2.7" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA042283 Enhanced NA NA "HPA042283: AB_10794417" "unprognostic (1.43e-2)" "unprognostic (7.84e-2)" "unprognostic (3.77e-3)" "unprognostic (1.41e-2)" "unprognostic (7.32e-2)" "unprognostic (9.81e-3)" "unprognostic (2.56e-1)" "unprognostic (7.48e-2)" "unprognostic (1.36e-1)" "unprognostic (1.18e-1)" "prognostic favorable (3.54e-4)" "unprognostic (1.23e-2)" "unprognostic (4.19e-10)" "unprognostic (8.04e-3)" "unprognostic (1.29e-1)" "unprognostic (3.60e-1)" "unprognostic (1.63e-1)" 1.8 26.5 27.1 2.7 57.4 1.8 1.8 12.7 67.1 1.7 2.6 3.6 0.0 5.0 1.7 1.9 1.8 2.0 1.8 1.7 31.8 98.9 1.7 1.7 1.9 2.0 25.1 39.8 1.7 6.3 1.7 47.7 1.7 33.9 1.8 2.4 0.7 2.1 2.0 1.7 1.9 3.8 2.1 14.3 1.9 4.1 4.3 4.8 0.0 1.9 0.0 1.9 1.7 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.6 0.1 0.8 0.3 0.0 0.0 0.0 0.3 0.6 0.6 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 0.2 0.3 0.0 0.0 0.3 0.0 0.1 0.0 0.8 1.1 0.0 1.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 0.1 1.0 0.0 1.1 0.0 0.0 0.3 0.3 0.0 0.0 0.4 0.1 0.0 0.0 0.0 2.7 0.0 0.0 0.9 0.1 0.1 0.0 0.0 0.0 0.3 0.0 0.1 2.7 0.0 0.0 0.3 0.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 1.3 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 27.1 57.4 12.7 45.9 31.8 98.9 25.1 39.8 33.9 4.8 0.0 0.0 0.0 0.0 0.2 84.4 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 0.0 0.1 68.3 18.7 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 8.1 0.9 0.0 0.4 0.2 31.1 0.0 0.8 1.4 2.6 0.0 0.2 0.0 0.0 0.0 CHAT ENSG00000070748 "Choline O-acetyltransferase" P28329 10 49609095-49665104 "Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins" "Neurotransmitter biosynthesis" "Acyltransferase, Transferase" "Congenital myasthenic syndrome, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 5.4;placenta: 10.4" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in single" 8 "basal ganglia: 5.4" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in many" "Cell line enriched" "Detected in some" 11 "NB-4: 15.9" "Region enhanced" "Detected in many" "basal ganglia: 18.4" "Group enriched" "Detected in all" 4 "basal ganglia: 7.7;pons and medulla: 8.1" "CAB002313, HPA048547, CAB079053" Supported Supported NA NA "CAB002313: AB_563661, CAB079053: , HPA048547: AB_2680437" "unprognostic (2.34e-2)" "unprognostic (6.10e-2)" "unprognostic (5.28e-2)" "unprognostic (6.96e-2)" "unprognostic (2.80e-2)" "unprognostic (3.98e-1)" "unprognostic (1.09e-1)" 0.2 0.0 0.2 0.3 5.4 0.0 0.2 0.2 0.2 0.2 0.6 0.2 0.2 1.6 0.2 0.5 0.2 0.0 0.2 0.2 0.2 0.6 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.9 0.0 0.2 10.4 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.2 1.1 0.2 0.4 0.2 0.0 0.5 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.6 1.0 0.3 0.2 0.6 1.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.5 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.6 0.0 0.0 1.1 15.9 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.7 0.0 0.1 0.0 0.7 0.4 0.1 0.0 0.1 0.1 0.3 0.1 0.0 0.1 0.0 0.1 0.0 1.4 0.0 0.0 0.2 0.3 0.4 0.1 0.5 0.3 1.0 0.4 0.1 0.6 0.5 0.3 0.0 0.6 0.1 1.0 0.2 0.0 0.2 5.4 0.2 0.2 0.2 0.6 0.2 0.2 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 DCLK3 "DCAMKL3, DCDC3C, KIAA1765" ENSG00000163673 "Doublecortin like kinase 3" Q9C098 3 36712422-36764349 "Enzymes, Predicted membrane proteins" "Kinase, Serine/threonine-protein kinase, Transferase" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in some" "brain: 10.0;testis: 8.0" "Cell type enriched" "Detected in some" 5 "Early spermatids: 24.4" "Cancer enhanced" "Detected in single" "testis cancer: 1.2" "Region enhanced" "Detected in many" "basal ganglia: 10.0" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "NTERA-2: 3.4;SCLC-21H: 3.3;SH-SY5Y: 2.7;U-2 OS: 1.9;U-2197: 2.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA040685 Approved NA NA "HPA040685: AB_2732487" "unprognostic (9.09e-3)" "unprognostic (1.41e-3)" "unprognostic (2.75e-1)" "unprognostic (2.66e-2)" "unprognostic (2.41e-1)" "unprognostic (1.80e-1)" "unprognostic (1.40e-2)" "unprognostic (1.08e-2)" "unprognostic (1.96e-2)" "unprognostic (1.86e-2)" "unprognostic (2.05e-1)" "unprognostic (7.07e-2)" "unprognostic (6.11e-5)" "unprognostic (7.94e-3)" "unprognostic (5.80e-2)" "unprognostic (3.25e-3)" "unprognostic (1.36e-2)" 1.1 0.4 2.6 1.4 10.0 0.3 0.1 0.1 2.3 0.5 0.2 0.3 0.0 0.5 0.3 0.1 0.1 0.2 0.6 0.9 1.4 0.9 0.0 0.1 0.3 0.2 0.6 0.0 0.0 0.2 0.4 1.8 1.1 0.4 0.3 0.3 1.3 1.7 0.2 2.7 0.4 0.4 0.9 0.7 0.1 0.0 8.0 3.2 0.0 0.9 0.0 0.3 0.5 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.2 0.9 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.3 2.7 0.1 0.3 0.0 0.2 0.0 0.4 0.3 0.0 1.9 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.6 10.0 0.1 2.3 1.4 0.9 0.6 0.0 0.4 3.2 0.0 0.0 0.0 0.0 0.0 5.0 1.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 24.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 5.2 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.7 0.0 0.7 0.7 0.2 0.0 0.0 0.0 0.0 0.0 DCX "DBCN, DC, LISX, SCLH, XLIS" ENSG00000077279 Doublecortin O43602 X 111293779-111412429 "Disease related genes, Predicted intracellular proteins" "Differentiation, Neurogenesis" "Developmental protein" "Disease mutation, Epilepsy, Lissencephaly" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 17.1;testis: 6.4" "Cell type enriched" "Detected in some" 12 "Rod photoreceptor cells: 22.7" "Cancer enriched" "Detected in some" 5 "glioma: 5.2" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "SCLC-21H: 34.6;SH-SY5Y: 14.2" "Region enriched" "Detected in many" 9 "olfactory region: 90.9" "Region enriched" "Detected in all" 5 "olfactory region: 130.1" HPA036121 Enhanced Supported Approved Cytosol NA NA Cytosol "HPA036121: AB_2674950" "unprognostic (1.36e-2)" "unprognostic (1.99e-1)" "unprognostic (7.36e-2)" "unprognostic (4.00e-2)" "unprognostic (1.50e-1)" "unprognostic (2.24e-1)" "unprognostic (2.00e-2)" "unprognostic (7.18e-2)" "unprognostic (3.24e-2)" "unprognostic (2.33e-3)" "unprognostic (3.67e-1)" "unprognostic (4.90e-4)" "unprognostic (5.02e-3)" "unprognostic (1.27e-1)" "unprognostic (1.85e-1)" 0.8 1.1 7.0 0.7 9.2 0.7 3.2 0.7 17.1 0.7 0.6 0.9 0.0 0.7 4.1 3.6 0.6 0.6 0.8 0.7 4.2 5.4 0.5 0.5 0.6 0.7 2.5 6.7 0.6 0.8 0.5 1.0 0.6 3.7 0.5 0.8 0.0 2.2 0.6 0.5 0.7 0.7 0.6 3.0 0.6 1.2 6.4 2.3 0.0 0.6 0.0 0.5 0.6 0.3 0.3 0.4 0.6 0.2 0.7 0.4 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 34.6 14.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.2 0.2 0.2 0.1 0.4 0.3 0.3 0.2 0.1 0.3 0.3 0.3 0.6 0.7 0.0 0.4 0.1 0.0 7.0 9.2 0.7 10.8 4.2 5.4 2.5 6.7 3.7 2.3 0.0 0.0 0.0 0.0 0.0 1.8 0.6 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 1.3 0.2 0.0 1.4 0.0 22.7 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 DNAH10 FLJ43808 ENSG00000197653 "Dynein axonemal heavy chain 10" Q8IVF4 12 123762188-123936206 "Predicted intracellular proteins" "Motor protein" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 10.0;epididymis: 10.1;fallopian tube: 9.5;lung: 11.8;testis: 16.4" "Cell type enhanced" "Detected in some" 22 "Ciliated cells: 104.4;Club cells: 20.5;Early spermatids: 27.9;Late spermatids: 49.5" "Cancer enhanced" "Detected in single" "testis cancer: 1.0" "Group enriched" "Detected in many" 4 "basal ganglia: 4.8;pons and medulla: 10.0" "Cell type enhanced" "Detected in some" "gdT-cell: 1.6;naive CD8 T-cell: 1.0" "Lineage enriched" "Detected in single" 13 "T-cells: 1.6" "Cell line enhanced" "Detected in some" "AN3-CA: 2.3;ASC diff: 3.9;SuSa: 2.4" HPA039066 Enhanced NA NA "HPA039066: AB_10673237" "unprognostic (1.37e-1)" "unprognostic (1.78e-1)" "unprognostic (6.08e-3)" "unprognostic (9.90e-3)" "unprognostic (2.16e-1)" "unprognostic (8.91e-2)" "unprognostic (3.39e-2)" "unprognostic (1.86e-1)" "unprognostic (5.59e-2)" "unprognostic (1.08e-2)" "unprognostic (7.28e-3)" "unprognostic (5.25e-2)" "unprognostic (1.61e-1)" "unprognostic (2.33e-1)" "unprognostic (7.23e-2)" "unprognostic (1.22e-2)" "unprognostic (9.11e-3)" 0.4 0.2 0.7 0.2 4.8 3.1 0.3 1.2 0.6 1.9 0.7 3.9 0.5 0.5 0.6 10.1 0.2 9.5 0.2 0.2 1.4 1.7 0.4 0.2 11.8 0.2 0.5 0.0 6.2 0.2 0.1 0.2 0.4 10.0 1.1 0.2 0.0 0.2 0.2 0.1 0.2 1.1 0.2 1.5 0.3 0.2 16.4 0.3 0.0 0.5 0.0 0.2 0.4 0.9 0.1 0.0 0.1 0.0 0.0 1.6 0.2 0.0 0.0 0.1 2.3 3.9 1.7 0.6 1.0 0.3 0.0 0.2 0.0 0.4 0.1 0.2 1.2 0.4 0.4 0.0 0.0 0.0 0.4 0.8 0.6 0.0 0.0 0.4 0.0 1.1 1.3 0.0 0.3 0.1 0.1 0.0 0.7 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.3 0.1 0.2 0.0 0.0 0.0 0.2 0.2 0.3 0.0 0.8 2.4 0.0 0.2 0.3 1.1 0.6 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.8 0.0 0.0 0.1 1.6 0.0 0.0 0.0 0.0 0.8 0.0 0.1 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.2 0.7 4.8 1.2 0.5 1.4 1.7 0.5 0.0 10.0 0.3 0.0 5.6 0.0 0.0 0.0 0.2 2.0 0.0 104.4 20.5 0.0 0.0 0.0 1.7 0.0 27.9 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 49.5 0.0 0.0 0.0 0.0 0.0 0.8 0.1 0.0 0.0 1.4 0.8 12.9 0.0 7.6 1.9 0.0 0.0 0.0 0.0 0.1 DNAI1 "CILD1, DIC1, PCD" ENSG00000122735 "Dynein axonemal intermediate chain 1" Q9UI46 9 34457414-34520989 "Disease related genes, Plasma proteins, Predicted intracellular proteins" "Cilium biogenesis/degradation" "Motor protein" "Ciliopathy, Disease mutation, Kartagener syndrome, Primary ciliary dyskinesia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 14.6;fallopian tube: 32.2;pituitary gland: 36.4;testis: 47.0" "Cell type enhanced" "Detected in some" 25 "Ciliated cells: 109.7;Late spermatids: 23.8;Spermatocytes: 48.1" "Cancer enhanced" "Detected in many" "endometrial cancer: 3.4" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 1.8;BEWO: 5.8;HDLM-2: 4.1;RPTEC TERT1: 2.2;SK-BR-3: 3.0;T-47d: 1.9" "Low region specificity" "Detected in many" "HPA021649, HPA021843" Enhanced NA NA "HPA021649: AB_1847913, HPA021843: AB_1847914" "unprognostic (9.61e-2)" "unprognostic (5.16e-2)" "unprognostic (4.59e-2)" "unprognostic (1.44e-3)" "unprognostic (3.72e-1)" "unprognostic (1.01e-1)" "unprognostic (1.92e-1)" "unprognostic (6.39e-2)" "unprognostic (4.38e-1)" "unprognostic (1.51e-1)" "unprognostic (8.16e-3)" "unprognostic (8.14e-2)" "unprognostic (2.74e-2)" "unprognostic (3.77e-2)" "unprognostic (2.94e-1)" "unprognostic (1.35e-1)" "unprognostic (1.13e-1)" 0.4 0.4 2.3 0.4 8.0 0.4 0.9 0.3 3.1 2.2 0.4 3.6 0.0 0.4 1.3 6.8 0.4 32.2 0.5 0.4 2.7 3.3 0.9 0.5 4.3 0.4 1.0 0.2 3.5 1.2 1.9 36.4 0.4 14.6 0.5 0.4 1.3 0.4 0.5 0.4 0.4 0.4 0.4 0.6 0.4 0.6 47.0 1.5 0.0 0.5 0.0 0.4 0.4 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.4 0.1 1.8 0.7 0.2 0.0 5.8 0.0 0.0 0.7 0.0 0.0 0.5 0.0 0.3 0.0 0.5 0.0 0.0 0.0 0.0 4.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.6 0.0 0.2 0.0 0.0 0.0 0.3 0.2 0.0 0.1 0.0 0.0 0.0 2.2 0.0 0.4 0.3 0.0 3.0 0.8 1.2 1.9 0.0 0.0 0.0 0.6 0.1 0.0 0.2 0.1 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 8.0 0.3 3.1 2.7 3.3 1.0 0.2 14.6 1.5 0.0 0.3 0.0 0.0 0.0 0.0 0.4 0.0 109.7 13.6 0.0 3.9 0.1 1.7 0.0 16.9 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 23.8 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.2 1.2 0.0 0.0 48.1 2.7 0.0 0.2 0.0 0.0 0.0 DNER "bet, UNQ26" ENSG00000187957 "Delta/notch like EGF repeat containing" Q8NFT8 2 229357629-229714558 "Cancer-related genes, Predicted membrane proteins" "Notch signaling pathway" "Activator, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 6 "adrenal gland: 45.6;brain: 85.2;salivary gland: 46.1" "Cell type enhanced" "Detected in many" 18 "Bipolar cells: 121.0;Intestinal endocrine cells: 27.5;Muller glia cells: 53.3;Rod photoreceptor cells: 35.9" "Cancer enriched" "Detected in many" 32 "glioma: 73.2" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "plasmacytoid DC: 1.4" "Lineage enhanced" "Detected in single" "dendritic cells: 1.4" "Group enriched" "Detected in some" 7 "GAMG: 71.3;hTERT-HME1: 29.1;hTERT-RPE1: 79.5;U-138 MG: 49.2;U-87 MG: 29.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA017320 Enhanced NA NA 2700000 "HPA017320: AB_1847808" "unprognostic (4.39e-2)" "unprognostic (1.83e-1)" "unprognostic (3.25e-1)" "unprognostic (1.00e-3)" "unprognostic (8.73e-2)" "unprognostic (6.23e-2)" "prognostic unfavorable (1.05e-4)" "unprognostic (4.23e-3)" "unprognostic (2.97e-1)" "unprognostic (1.17e-1)" "unprognostic (1.60e-1)" "unprognostic (8.60e-2)" "prognostic unfavorable (3.42e-4)" "unprognostic (2.59e-2)" "unprognostic (7.32e-2)" "unprognostic (5.63e-2)" "unprognostic (5.13e-3)" 1.7 45.6 25.4 2.2 26.8 1.3 3.1 19.5 85.2 2.2 2.3 38.4 0.0 1.6 2.1 5.7 1.5 4.1 1.5 6.8 23.9 36.8 9.7 1.3 2.0 1.5 39.8 15.2 1.6 1.9 1.7 9.6 1.5 30.0 2.8 2.2 2.5 46.1 1.6 1.3 2.5 1.9 2.2 26.4 1.3 8.3 2.0 30.4 0.0 1.4 0.0 2.1 1.4 0.2 0.0 1.4 0.0 0.3 0.0 0.0 0.0 0.0 0.3 0.7 0.0 0.1 0.1 0.0 0.0 0.2 1.6 0.5 0.0 0.2 0.0 0.0 0.0 71.3 0.0 0.0 0.2 0.8 0.0 0.0 0.0 2.6 0.0 0.2 0.0 0.0 0.5 1.7 1.2 29.1 79.5 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.0 2.6 0.0 0.3 0.0 2.8 0.0 5.8 0.5 0.1 0.0 0.1 0.0 0.0 0.0 0.0 49.2 0.0 1.6 7.3 0.0 0.0 0.0 29.1 0.0 2.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.3 1.4 0.0 0.0 25.4 26.8 19.5 26.6 23.9 36.8 39.8 15.2 30.0 30.4 0.0 0.0 0.0 5.8 0.3 121.0 10.3 0.0 14.7 0.0 3.5 13.7 0.0 1.7 0.2 6.8 0.0 0.0 0.0 1.2 0.1 0.8 3.8 0.0 0.0 0.1 11.1 27.5 0.0 0.0 1.3 5.5 1.0 18.6 0.0 0.0 53.3 0.5 0.0 5.6 0.8 35.9 0.0 0.5 0.7 1.1 0.0 0.1 0.0 0.0 0.4 FGF11 "FHF3, FLJ16061, MGC102953, MGC45269" ENSG00000161958 "Fibroblast growth factor 11" Q92914 17 7438273-7444937 "Predicted intracellular proteins" "Growth factor" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "adrenal gland: 23.5" "Cell type enhanced" "Detected in many" 10 "Horizontal cells: 17.5;Muller glia cells: 12.7;Suprabasal keratinocytes: 8.4" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in single" "eosinophil: 1.6" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "A-431: 9.4;HaCaT: 17.3;LHCN-M2: 11.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA066605, HPA075188" Enhanced Approved Centrosome NA NA Centrosome "HPA066605: AB_2685693, HPA075188: AB_2732283" "unprognostic (7.35e-2)" "unprognostic (1.14e-2)" "unprognostic (7.67e-3)" "unprognostic (2.79e-4)" "unprognostic (9.15e-2)" "unprognostic (3.28e-2)" "unprognostic (7.31e-2)" "unprognostic (3.11e-2)" "unprognostic (1.59e-2)" "unprognostic (1.45e-1)" "unprognostic (4.69e-2)" "unprognostic (2.89e-3)" "unprognostic (2.00e-6)" "unprognostic (1.12e-1)" "unprognostic (2.30e-1)" "unprognostic (6.90e-3)" "unprognostic (4.97e-3)" 3.3 23.5 10.5 3.0 13.8 2.1 2.9 4.5 11.6 6.4 1.6 4.6 0.1 1.8 3.1 1.9 13.0 1.7 3.2 11.6 11.7 4.6 3.4 1.1 1.3 6.2 8.1 5.2 1.6 1.3 1.5 1.0 2.0 10.6 1.4 1.4 6.8 3.7 1.7 8.8 19.7 1.3 2.9 4.1 2.4 1.6 2.8 9.9 2.5 7.2 7.1 9.0 2.9 8.7 0.0 0.0 1.6 0.6 0.0 0.3 0.0 9.4 0.6 5.3 0.0 3.1 0.1 2.7 0.2 3.3 0.3 0.6 0.2 1.0 2.8 0.7 0.1 0.1 17.3 2.0 5.4 1.2 5.9 4.2 5.2 0.5 1.3 0.5 0.2 5.8 0.6 1.5 0.4 0.2 0.5 0.2 2.2 2.0 0.2 11.4 2.1 1.7 2.3 1.9 0.4 0.2 4.5 4.8 1.2 0.7 0.8 1.1 5.4 0.6 0.6 0.4 3.1 0.3 0.4 0.2 0.3 5.7 0.0 0.2 0.4 1.3 0.9 1.3 3.2 0.6 0.0 0.0 1.6 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.6 0.0 0.3 0.0 10.5 13.8 4.5 11.6 11.7 4.6 8.1 5.2 10.6 9.9 0.0 0.0 0.0 0.3 4.8 2.8 0.4 2.5 0.0 0.0 1.8 5.9 0.3 3.3 0.5 1.3 0.8 0.4 0.0 0.2 0.4 0.4 0.5 0.0 0.0 0.3 17.5 0.0 0.6 0.3 3.4 1.7 0.3 1.7 0.0 0.3 12.7 1.0 0.0 2.1 0.1 2.5 0.0 0.9 1.2 1.3 8.4 0.6 0.0 0.6 0.9 FGF2 FGFB ENSG00000138685 "Fibroblast growth factor 2" P09038 4 122826708-122898236 "Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins, Transporters" "Angiogenesis, Differentiation" "Developmental protein, Growth factor, Heparin-binding, Mitogen" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell type enhanced" "Detected in many" 5 "Fibroblasts: 12.4;Smooth muscle cells: 15.5" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in many" "BJ: 57.4;BJ hTERT+: 33.7;fHDF/TERT166: 62.3;hTERT-HME1: 34.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB000125, HPA065502" Enhanced Supported "Nucleoplasm,Nuclear bodies" "Secreted in other tissues" NA NA 92500 "Nucleoplasm, Nuclear bodies" "CAB000125: , HPA065502: " "unprognostic (1.53e-2)" "unprognostic (3.12e-1)" "unprognostic (1.08e-1)" "unprognostic (7.42e-2)" "unprognostic (2.10e-1)" "unprognostic (3.33e-1)" "unprognostic (6.98e-2)" "unprognostic (1.25e-1)" "unprognostic (2.82e-1)" "unprognostic (1.79e-1)" "prognostic unfavorable (9.85e-4)" "unprognostic (3.37e-1)" "unprognostic (4.61e-3)" "unprognostic (2.36e-1)" "unprognostic (1.81e-1)" "unprognostic (4.45e-2)" "unprognostic (3.45e-3)" 28.1 3.8 19.4 6.9 21.3 0.7 12.1 6.5 15.3 10.2 14.2 10.3 1.9 2.6 17.9 6.3 6.4 10.1 9.4 5.6 17.1 11.0 5.5 2.9 8.3 2.5 9.9 10.7 16.8 2.4 10.1 4.0 8.1 18.6 10.3 5.6 7.5 4.6 11.9 2.0 2.3 4.1 16.2 17.3 1.9 7.6 3.0 12.3 0.0 3.1 3.8 2.7 7.5 14.5 0.8 0.8 0.5 0.5 0.3 1.0 0.0 1.2 3.1 1.8 6.9 4.4 7.4 0.0 57.4 33.7 24.1 14.0 0.0 0.1 0.0 6.7 62.3 19.0 0.2 1.8 0.1 24.3 4.5 0.8 0.0 6.5 0.0 13.0 0.3 0.0 3.9 0.4 23.8 34.4 12.1 2.6 0.0 1.7 1.9 6.2 0.0 0.0 0.0 5.2 0.0 1.4 0.0 0.9 0.0 7.6 0.0 1.0 0.9 11.1 0.0 0.4 10.8 0.0 0.1 2.4 20.0 3.9 7.4 4.9 3.4 3.6 0.0 5.7 0.0 2.1 0.5 0.5 0.4 0.3 0.4 0.2 0.4 0.5 0.4 0.2 0.8 0.7 1.0 0.4 0.3 0.4 0.8 0.7 0.0 19.4 21.3 6.5 15.3 17.1 11.0 9.9 10.7 18.6 12.3 6.0 0.0 0.0 1.5 1.4 3.5 3.9 0.0 0.0 2.3 7.0 0.0 1.8 3.3 6.9 8.7 5.8 0.0 0.0 0.8 0.0 12.4 5.2 0.0 0.4 0.4 0.0 1.7 7.4 0.0 2.5 9.2 0.9 5.0 1.0 0.0 8.4 6.7 0.0 7.8 0.4 1.8 0.0 15.5 3.1 0.2 1.1 4.0 0.0 0.0 0.3 GNAL ENSG00000141404 "G protein subunit alpha L" P38405 18 11688956-11885685 "Disease related genes, Predicted intracellular proteins" Transducer "Disease mutation, Dystonia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 82.7" "Cell type enhanced" "Detected in many" 4 "Cone photoreceptor cells: 15.7" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 5 "basal ganglia: 82.7" "Group enriched" "Detected in some" 4 "basophil: 1.1;gdT-cell: 4.2;memory CD8 T-cell: 2.9;naive CD8 T-cell: 2.2;neutrophil: 1.7" "Group enriched" "Detected in many" 5 "granulocytes: 1.7;T-cells: 4.2" "Cell line enhanced" "Detected in many" "Daudi: 18.4;HeLa: 18.8;U-2 OS: 9.7" "Low region specificity" "Detected in all" "Region enriched" "Detected in many" 13 "basal ganglia: 183.9" "CAB015464, HPA051160" Enhanced Approved Nucleoplasm,Cytosol NA NA "Nucleoplasm, Cytosol" "CAB015464: AB_831819, HPA051160: AB_2732564" "unprognostic (2.29e-3)" "unprognostic (7.43e-2)" "unprognostic (8.14e-3)" "unprognostic (3.41e-5)" "unprognostic (4.71e-2)" "unprognostic (9.58e-3)" "unprognostic (9.93e-3)" "unprognostic (1.87e-1)" "unprognostic (2.36e-1)" "unprognostic (7.17e-2)" "unprognostic (1.82e-3)" "unprognostic (6.05e-2)" "unprognostic (1.23e-3)" "unprognostic (1.09e-1)" "unprognostic (3.85e-2)" "unprognostic (4.26e-2)" "unprognostic (7.03e-2)" 7.2 1.5 17.8 3.0 82.7 0.7 4.2 2.7 18.1 8.0 3.7 3.2 3.3 1.6 6.7 2.4 8.2 4.1 4.6 2.2 7.1 7.6 4.2 1.3 2.5 5.1 6.6 5.3 3.2 1.3 1.0 20.7 2.9 8.8 9.9 3.7 2.1 4.6 18.1 18.3 7.0 2.0 9.9 3.3 1.8 2.1 6.2 11.3 0.9 8.0 1.4 5.7 9.5 7.7 0.4 0.2 1.7 0.2 0.5 4.2 1.4 0.5 6.1 7.4 0.5 0.6 0.1 0.8 0.1 0.2 0.5 0.0 6.5 1.1 18.4 1.2 0.1 4.2 0.3 6.9 5.9 0.0 3.8 6.3 0.1 18.8 3.7 0.0 0.2 0.4 0.9 8.8 0.0 0.1 0.3 0.0 0.2 1.6 0.2 0.2 0.2 0.2 0.5 6.1 5.0 0.1 0.1 1.0 0.2 0.4 0.2 6.9 0.1 8.6 0.4 2.1 1.8 0.2 0.2 1.0 0.7 9.7 0.3 1.8 0.3 0.1 0.1 0.3 0.2 0.2 1.1 0.2 0.4 4.2 0.1 0.1 0.4 0.5 2.9 0.0 0.3 0.2 2.2 1.7 0.5 0.1 0.2 0.1 1.4 17.8 82.7 2.7 12.7 7.1 7.6 6.6 5.3 8.8 11.3 3.0 5.1 0.0 10.1 9.4 6.7 3.4 0.0 13.4 7.9 3.5 15.7 0.4 1.7 0.4 3.6 4.4 1.4 0.0 2.7 2.8 5.6 4.9 5.7 1.3 0.9 3.2 0.0 0.6 0.3 2.2 0.9 1.3 13.5 0.0 0.2 0.9 1.2 2.0 2.8 3.8 3.1 6.5 13.9 1.9 5.3 6.6 0.5 1.3 1.2 12.9 GNG12 ENSG00000172380 "G protein subunit gamma 12" Q9UBI6 1 67701466-67833467 "Predicted intracellular proteins, RAS pathway related proteins" Transducer "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell type specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low cell line specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA057790, HPA062208" Enhanced Supported Approved Mitochondria NA NA Mitochondria "HPA057790: AB_2683527, HPA062208: AB_2684711" "unprognostic (5.18e-2)" "unprognostic (1.76e-3)" "unprognostic (4.46e-3)" "unprognostic (7.77e-2)" "unprognostic (1.06e-1)" "unprognostic (4.71e-2)" "unprognostic (5.29e-2)" "unprognostic (5.84e-3)" "unprognostic (5.50e-2)" "unprognostic (3.41e-2)" "unprognostic (4.46e-3)" "unprognostic (8.13e-2)" "unprognostic (4.12e-3)" "unprognostic (2.33e-2)" "unprognostic (9.33e-2)" "unprognostic (7.78e-2)" "unprognostic (2.14e-3)" 28.7 23.8 10.3 13.8 9.4 0.0 49.4 5.1 7.7 28.3 34.5 10.9 16.6 40.1 41.5 20.7 34.0 21.2 27.2 14.2 11.8 9.3 36.1 15.4 16.4 12.4 9.1 6.3 24.9 16.0 23.9 17.1 40.1 14.3 21.4 22.2 14.6 16.4 19.3 9.0 33.0 86.2 51.8 22.9 17.5 19.5 11.6 9.6 3.6 23.1 20.5 16.5 31.5 26.7 0.0 0.0 0.0 0.0 0.7 0.0 0.0 10.0 9.4 10.0 5.4 42.8 37.2 10.3 31.1 40.6 27.5 24.8 4.4 9.9 0.0 13.3 43.5 17.2 7.5 6.2 25.5 48.5 0.0 4.8 0.1 8.4 0.0 17.1 0.0 0.5 22.3 15.3 29.3 38.9 38.7 43.1 0.0 0.5 0.0 30.1 1.7 0.0 0.0 7.6 11.0 11.7 0.0 20.7 0.1 26.4 9.0 2.3 4.6 21.5 9.0 41.7 8.9 4.6 0.1 55.4 32.0 20.9 57.5 19.1 0.5 0.0 0.0 20.2 1.2 43.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 10.3 9.4 5.1 7.7 11.8 9.3 9.1 6.3 14.3 9.6 50.6 25.1 2.4 66.8 178.8 1.5 25.9 48.4 69.6 34.2 55.8 5.9 52.0 63.0 84.4 7.6 66.7 171.8 0.0 120.2 89.1 65.8 79.6 3.5 38.9 22.5 3.2 33.4 86.0 16.9 10.4 66.2 12.4 74.2 6.4 58.8 1.3 115.9 90.3 71.1 129.0 17.2 51.8 74.6 1.7 24.7 189.6 147.1 4.3 51.3 91.1 GNG7 FLJ00058 ENSG00000176533 "G protein subunit gamma 7" O60262 19 2511219-2702709 "Predicted intracellular proteins, RAS pathway related proteins" Transducer "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 5 "brain: 115.9" "Group enriched" "Detected in many" 5 "B-cells: 132.4;Cardiomyocytes: 52.7;Distal tubular cells: 104.5;Hofbauer cells: 49.0;Horizontal cells: 160.5;Melanocytes: 49.0;Muller glia cells: 53.2" "Cancer enhanced" "Detected in all" "glioma: 21.9" "Region enriched" "Detected in all" 5 "basal ganglia: 115.9" "Group enriched" "Detected in many" 4 "memory B-cell: 23.9;naive B-cell: 20.5;plasmacytoid DC: 19.9" "Group enriched" "Detected in many" 4 "B-cells: 23.9;dendritic cells: 19.9" "Cell line enhanced" "Detected in many" "Daudi: 10.5;REH: 31.0;SK-MEL-30: 14.3;U-266/70: 29.8;U-266/84: 13.7" "Region enriched" "Detected in many" 6 "basal ganglia: 1142.7" "Region enriched" "Detected in all" 6 "basal ganglia: 484.6" HPA057790 Supported Supported NA NA "HPA057790: AB_2683527" "unprognostic (3.97e-3)" "unprognostic (1.16e-4)" "unprognostic (4.92e-2)" "unprognostic (2.72e-1)" "unprognostic (2.79e-1)" "unprognostic (8.42e-4)" "prognostic favorable (3.05e-4)" "prognostic favorable (1.35e-5)" "unprognostic (1.27e-2)" "unprognostic (4.95e-2)" "prognostic favorable (3.71e-4)" "unprognostic (1.27e-1)" "prognostic favorable (0.00e+0)" "unprognostic (6.96e-2)" "unprognostic (1.46e-1)" "unprognostic (6.36e-2)" "unprognostic (4.96e-2)" 3.1 4.8 19.8 4.5 115.9 5.4 4.1 9.7 28.2 2.6 3.8 23.4 0.8 4.7 4.8 4.9 11.1 6.5 3.3 22.5 20.3 11.4 6.0 2.2 3.0 8.0 20.0 10.0 10.0 7.2 5.4 4.6 1.4 20.9 7.1 3.0 12.2 22.8 5.7 2.9 1.7 4.9 3.4 28.5 11.0 5.8 5.5 22.0 0.1 3.7 0.4 8.2 3.4 1.4 23.9 19.9 5.0 0.6 0.0 0.5 1.3 0.1 0.0 1.5 3.4 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.3 10.5 0.5 0.1 0.1 0.1 1.7 0.0 0.0 0.0 1.4 0.2 0.0 1.2 0.8 0.0 6.3 0.2 0.2 0.0 0.1 0.1 0.0 1.2 0.1 6.8 0.0 1.0 0.2 0.6 1.2 0.2 0.6 31.0 0.0 2.8 0.1 0.0 0.0 4.5 0.0 0.0 14.3 1.1 0.2 2.6 0.0 0.0 1.5 0.1 0.1 29.8 13.7 2.2 0.1 3.3 7.9 1.1 0.6 3.2 0.1 0.2 0.4 23.9 0.2 0.1 2.5 20.5 0.5 0.3 5.0 0.0 0.0 19.9 0.0 1.3 19.8 115.9 9.7 20.0 20.3 11.4 20.0 10.0 20.9 22.0 6.0 3.4 132.4 10.1 2.3 5.4 52.7 10.2 5.3 5.7 8.7 7.9 0.5 104.5 10.7 4.3 12.1 0.5 0.0 4.2 0.9 1.7 8.1 12.7 11.6 49.0 160.5 5.8 14.7 7.2 7.4 2.3 6.6 49.0 12.6 2.6 53.2 3.9 1.5 2.5 15.8 10.2 6.5 8.0 1.7 2.9 1.8 2.9 2.2 1.7 6.7 GPRC5B RAIG-2 ENSG00000167191 "G protein-coupled receptor class C group 5 member B" Q9NZH0 16 19856691-19886167 "G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 108.0" "Cell type enhanced" "Detected in many" 11 "Early spermatids: 172.9;Late spermatids: 145.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 4 "naive CD4 T-cell: 6.5" "Lineage enriched" "Detected in many" 4 "T-cells: 6.5" "Cell line enhanced" "Detected in many" "EFO-21: 39.2;HHSteC: 26.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA015247 Enhanced Supported Nucleoplasm,Nucleoli,Vesicles NA NA Vesicles "Nucleoplasm, Nucleoli" "HPA015247: AB_1849323" "unprognostic (1.26e-1)" "unprognostic (1.32e-1)" "prognostic unfavorable (9.27e-5)" "unprognostic (2.60e-3)" "unprognostic (3.28e-1)" "unprognostic (2.46e-1)" "unprognostic (3.97e-2)" "unprognostic (5.70e-2)" "unprognostic (1.42e-1)" "unprognostic (2.26e-2)" "unprognostic (2.76e-2)" "unprognostic (1.27e-1)" "prognostic favorable (6.30e-4)" "unprognostic (4.73e-2)" "unprognostic (1.06e-1)" "unprognostic (4.42e-3)" "unprognostic (6.78e-3)" 12.6 4.4 45.2 3.2 55.9 1.0 7.3 22.8 108.0 5.4 2.9 95.1 4.9 4.0 7.1 9.3 5.5 12.7 9.2 22.3 47.8 28.7 12.1 2.7 3.9 4.6 63.1 34.9 13.7 12.7 9.5 3.8 9.3 38.6 6.3 2.3 3.8 20.8 11.5 35.1 2.5 3.3 5.1 61.6 2.2 22.7 19.6 63.1 0.0 7.2 2.6 2.7 6.2 3.0 0.0 0.0 0.0 1.5 0.0 6.5 1.3 0.4 12.6 12.5 2.2 12.9 0.9 2.3 0.1 3.1 1.2 0.8 11.5 0.4 0.0 39.2 0.4 8.2 0.6 9.2 0.0 0.7 0.0 3.3 0.0 0.0 0.0 26.8 0.0 0.0 1.1 0.0 2.1 0.0 3.3 6.1 0.3 2.6 0.2 2.8 0.6 0.0 0.0 13.7 0.0 6.0 3.6 0.0 0.0 0.4 5.8 9.7 0.8 1.4 0.8 11.3 4.1 0.0 0.2 1.2 0.0 1.5 6.1 0.3 0.1 0.0 0.0 0.6 0.1 0.7 0.0 0.1 0.0 0.0 1.5 0.0 0.0 1.6 0.0 0.0 0.0 6.5 0.0 0.0 0.0 0.3 0.0 0.0 1.3 45.2 55.9 22.8 40.5 47.8 28.7 63.1 34.9 38.6 63.1 0.0 4.0 0.9 4.6 1.1 30.1 13.4 35.7 5.3 7.9 29.6 0.0 3.9 1.7 47.7 172.9 30.1 0.0 0.0 56.2 1.2 9.7 4.3 0.0 0.0 3.3 0.0 0.0 6.2 1.0 145.0 22.2 1.1 15.1 1.8 0.0 20.5 53.7 0.0 25.1 0.1 5.7 12.9 9.2 2.8 1.5 1.5 2.1 0.0 0.0 1.7 GRIK4 "GluK4, GRIK, KA1" ENSG00000149403 "Glutamate ionotropic receptor kainate type subunit 4" Q16099 11 120511700-120988904 "Predicted membrane proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "brain: 19.3;ovary: 8.5" "Cell type enriched" "Detected in some" 8 "Cone photoreceptor cells: 33.4" "Cancer enriched" "Detected in some" 5 "glioma: 3.1" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "HDLM-2: 6.4;HEL: 19.7;T-47d: 5.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA074453 Enhanced NA NA "HPA074453: AB_2732255" "unprognostic (9.63e-2)" "unprognostic (4.96e-2)" "unprognostic (1.58e-1)" "unprognostic (2.49e-1)" "unprognostic (2.37e-1)" "unprognostic (6.64e-4)" "unprognostic (1.48e-2)" "unprognostic (7.26e-2)" "unprognostic (3.16e-1)" "unprognostic (2.38e-1)" "unprognostic (4.53e-2)" "unprognostic (2.50e-1)" "unprognostic (4.84e-11)" "unprognostic (1.35e-1)" "unprognostic (2.81e-1)" "unprognostic (4.47e-3)" "unprognostic (2.58e-2)" 1.0 5.4 11.3 1.0 9.0 0.8 1.3 3.9 19.3 1.2 1.1 9.4 0.0 1.2 1.1 0.9 1.2 1.7 1.1 1.6 13.9 7.2 1.0 0.8 3.1 1.0 8.7 11.0 8.5 0.8 0.8 2.6 1.5 12.3 1.5 1.1 0.0 1.1 1.0 1.0 1.3 1.2 1.0 6.3 1.4 0.9 2.0 8.2 0.0 6.3 0.0 1.0 1.2 0.4 0.0 0.0 0.0 0.0 0.7 0.5 0.1 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.5 0.0 0.0 0.0 0.5 0.0 0.0 6.4 0.6 19.7 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.2 0.0 0.0 0.0 0.6 5.1 0.0 0.2 0.0 0.2 0.0 0.0 2.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.1 11.3 9.0 3.9 14.0 13.9 7.2 8.7 11.0 12.3 8.2 0.0 1.1 0.0 0.0 0.0 0.4 1.2 0.0 0.0 0.0 0.0 33.4 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.0 0.0 0.0 0.0 0.3 4.1 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 2.7 0.0 0.1 0.0 0.0 0.4 GRIN1 "GluN1, NMDAR1" ENSG00000176884 "Glutamate ionotropic receptor NMDA type subunit 1" Q05586 9 137138390-137168762 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters" "Ion transport, Transport" "Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets, Mental retardation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 38 "brain: 97.5" "Cell type enhanced" "Detected in some" 10 "Bipolar cells: 5.6;Cardiomyocytes: 2.4;monocytes: 3.6;Rod photoreceptor cells: 5.7" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "OE19: 2.6;REH: 3.1;RPMI-8226: 4.3;SCLC-21H: 10.0;SH-SY5Y: 6.9;T-47d: 2.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA067773 Enhanced NA NA "HPA067773: " "unprognostic (3.58e-2)" "unprognostic (4.51e-1)" "unprognostic (2.68e-2)" "unprognostic (5.48e-4)" "unprognostic (5.20e-2)" "unprognostic (1.25e-1)" "unprognostic (2.34e-2)" "unprognostic (2.81e-2)" "unprognostic (6.46e-3)" "unprognostic (1.51e-1)" "unprognostic (1.69e-1)" "unprognostic (1.78e-1)" "unprognostic (1.21e-3)" "unprognostic (4.47e-2)" "unprognostic (1.44e-1)" "unprognostic (3.56e-3)" "unprognostic (4.72e-2)" 1.7 2.0 23.6 2.0 47.5 1.7 1.8 28.1 97.5 1.8 2.0 3.2 0.0 2.2 1.7 1.8 1.7 1.7 1.7 1.7 29.1 26.4 1.8 1.7 1.8 1.8 15.4 37.9 1.7 1.8 1.8 0.0 1.7 22.0 2.2 1.8 0.7 2.5 1.8 1.7 1.8 2.2 1.8 4.7 1.8 1.8 1.9 6.3 0.0 1.7 0.0 1.8 1.8 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 1.7 0.0 0.1 0.0 0.0 0.4 1.0 0.0 0.1 0.0 0.0 1.2 0.0 0.0 0.0 1.5 0.1 0.0 0.2 0.2 0.0 0.1 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.9 0.0 0.0 0.1 2.6 0.0 3.1 0.0 4.3 0.0 0.0 10.0 6.9 0.1 0.6 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 23.6 47.5 28.1 87.9 29.1 26.4 15.4 37.9 22.0 6.3 0.0 0.0 0.0 0.4 0.0 5.6 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 1.1 0.0 0.0 0.0 0.3 0.0 0.0 0.8 0.0 0.0 0.1 1.6 1.7 0.0 0.0 0.4 0.0 0.0 0.0 3.6 1.7 1.6 0.3 0.0 0.0 0.0 5.7 0.0 0.0 0.2 1.3 0.0 0.0 0.0 0.0 0.3 HCN4 ENSG00000138622 "Hyperpolarization activated cyclic nucleotide gated potassium channel 4" Q9Y3Q4 15 73319859-73369264 "Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Sodium transport, Transport" "Ion channel, Ligand-gated ion channel, Potassium channel, Sodium channel, Voltage-gated channel" "Brugada syndrome, Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 4.3;heart muscle: 12.5;testis: 9.6" "Group enriched" "Detected in some" 7 "Early spermatids: 28.7;Late spermatids: 33.9" "Group enriched" "Detected in some" 8 "testis cancer: 3.1;thyroid cancer: 0.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 2.6;CACO-2: 3.2;HDLM-2: 2.1;NTERA-2: 9.5;SuSa: 2.5;U-2 OS: 4.2" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA073174 Approved NA NA "HPA073174: " "unprognostic (2.21e-1)" "unprognostic (1.39e-1)" "unprognostic (2.18e-2)" "unprognostic (3.14e-2)" "unprognostic (5.30e-3)" "unprognostic (1.92e-2)" "unprognostic (2.19e-1)" "unprognostic (3.50e-2)" "unprognostic (2.37e-1)" "unprognostic (6.56e-2)" "unprognostic (1.13e-3)" "unprognostic (1.13e-1)" "unprognostic (6.05e-5)" "unprognostic (5.56e-2)" "unprognostic (4.60e-2)" "unprognostic (1.51e-2)" "unprognostic (7.95e-2)" 0.2 1.3 4.3 0.2 1.1 0.1 0.1 0.9 3.4 0.2 0.4 2.1 0.0 1.2 0.1 0.2 0.1 0.3 0.2 12.5 0.6 2.0 0.4 0.1 0.3 0.1 1.8 0.9 0.1 0.2 0.1 2.1 0.1 3.9 0.6 0.3 0.2 0.1 1.0 0.1 0.2 0.4 0.2 0.7 0.1 0.6 9.6 1.9 0.0 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.2 0.0 1.5 0.0 0.6 0.2 0.0 0.0 0.1 2.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 9.5 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.1 0.0 0.5 0.0 0.0 2.5 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 1.1 0.9 3.4 0.6 2.0 1.8 0.9 3.9 1.9 0.0 0.0 0.0 0.0 0.0 0.5 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 28.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 33.9 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.0 1.2 0.0 0.1 0.6 1.3 0.0 0.0 0.0 0.0 0.0 HTR6 "5-HT6, 5-HT6R" ENSG00000158748 "5-hydroxytryptamine receptor 6" P50406 1 19665287-19679562 "FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins" "G-protein coupled receptor, Receptor, Transducer" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 9 "brain: 24.6" "Not detected" "Not detected" "Cancer enhanced" "Detected in single" "renal cancer: 0.6" "Group enriched" "Detected in many" 5 "basal ganglia: 24.6;cerebral cortex: 6.6" "Cell type enhanced" "Detected in some" "MAIT T-cell: 1.4;naive CD4 T-cell: 1.1" "Lineage enriched" "Detected in single" 14 "T-cells: 1.4" "Cell line enhanced" "Detected in some" "MCF7: 1.2;NTERA-2: 2.4;SH-SY5Y: 6.7" "Low region specificity" "Detected in many" "Region enhanced" "Detected in many" "basal ganglia: 9.5" HPA068165 Uncertain NA NA "HPA068165: " "unprognostic (2.34e-2)" "unprognostic (1.84e-1)" "unprognostic (7.19e-3)" "unprognostic (3.84e-5)" "unprognostic (1.38e-4)" "unprognostic (2.69e-2)" "unprognostic (1.36e-1)" "unprognostic (2.80e-2)" "unprognostic (1.03e-1)" "unprognostic (5.33e-3)" "unprognostic (8.63e-2)" "unprognostic (5.47e-4)" "unprognostic (1.28e-1)" "unprognostic (2.49e-1)" "unprognostic (6.13e-3)" "unprognostic (2.02e-1)" 0.4 0.5 1.2 1.4 24.6 0.4 0.4 0.2 6.6 0.6 0.4 0.0 0.0 0.6 0.6 0.5 0.5 0.6 0.5 0.4 1.4 1.0 0.3 0.3 0.3 1.4 0.5 2.2 0.3 0.3 0.3 0.4 0.3 0.4 0.4 0.3 0.0 0.5 0.3 0.3 0.8 0.5 0.5 0.2 0.4 0.5 0.8 3.2 0.0 0.3 0.0 2.7 0.6 0.2 0.0 0.0 0.0 0.0 0.0 1.4 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.2 0.0 0.0 2.4 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 6.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.0 1.4 0.0 1.0 0.5 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.2 0.2 1.2 24.6 0.2 6.6 1.4 1.0 0.5 2.2 0.4 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 KCND2 "KIAA1044, Kv4.2, RK5" ENSG00000184408 "Potassium voltage-gated channel subfamily D member 2" Q9NZV8 7 120273668-120750331 "Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Autism, Autism spectrum disorder, Disease mutation, Epilepsy, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 41.1" "Cell type enhanced" "Detected in some" 9 "Bipolar cells: 2.9;Cholangiocytes: 5.1;Ductal cells: 2.5;Leydig cells: 3.4;Spermatocytes: 4.2;Spermatogonia: 3.3" "Cancer enhanced" "Detected in many" "glioma: 6.2" "Region enhanced" "Detected in all" "cerebellum: 41.1" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "ASC TERT1: 6.5;HSkMC: 4.1;NTERA-2: 3.2;RT4: 3.3;SCLC-21H: 16.6" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA029068 Enhanced NA NA "HPA029068: AB_10601436" "unprognostic (4.22e-1)" "unprognostic (2.79e-4)" "unprognostic (3.79e-2)" "unprognostic (3.40e-1)" "unprognostic (1.23e-1)" "unprognostic (3.91e-2)" "unprognostic (4.98e-3)" "unprognostic (9.07e-3)" "unprognostic (1.03e-1)" "unprognostic (1.14e-1)" "unprognostic (9.77e-3)" "unprognostic (1.51e-1)" "unprognostic (4.51e-4)" "unprognostic (4.07e-5)" "unprognostic (2.71e-2)" "unprognostic (2.92e-2)" "unprognostic (1.83e-3)" 2.9 1.0 3.9 1.0 6.7 0.3 1.9 41.1 20.6 2.4 0.7 1.5 0.0 0.7 5.6 0.5 0.5 1.7 7.0 0.5 3.7 5.4 0.3 0.4 0.6 0.5 4.2 3.6 5.9 0.6 2.5 6.6 0.8 12.1 0.5 0.6 0.0 0.7 1.7 0.5 0.3 0.5 3.7 3.7 0.3 0.5 2.9 4.5 0.0 0.8 1.1 0.3 2.2 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.7 6.5 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.1 2.6 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.7 0.0 0.0 4.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.4 0.2 0.0 0.0 0.0 3.2 0.0 0.2 0.0 0.0 0.0 0.0 3.3 16.6 0.0 0.0 0.0 0.0 0.2 0.2 0.8 0.0 0.5 0.0 0.0 0.0 0.7 0.0 0.0 0.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 6.7 41.1 5.3 3.7 5.4 4.2 3.6 12.1 4.5 0.0 0.0 0.0 0.0 0.0 2.9 1.2 5.1 0.0 0.0 0.0 0.0 0.0 0.0 2.5 2.3 0.1 0.0 0.0 0.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 1.4 3.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.5 0.0 0.4 4.2 3.3 0.1 0.0 0.0 0.0 0.1 KCNH8 "elk3, Kv12.1" ENSG00000183960 "Potassium voltage-gated channel subfamily H member 8" Q96L42 3 19148454-19535646 "Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Potassium transport, Transport" "Ion channel, Potassium channel, Voltage-gated channel" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Tissue enhanced" "Detected in many" "brain: 31.3;pituitary gland: 16.1" "Cell type enhanced" "Detected in some" 8 "Bipolar cells: 4.7;Early spermatids: 2.7;Intestinal endocrine cells: 3.5;Melanocytes: 3.3;Muller glia cells: 3.7" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "memory B-cell: 2.1;naive B-cell: 4.5" "Lineage enriched" "Detected in single" 5 "B-cells: 4.5" "Cell line enhanced" "Detected in some" "HAP1: 2.1;OE19: 4.0;SH-SY5Y: 9.4" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA016586, HPA077537, HPA077773" Approved Supported "Plasma membrane" NA NA "Plasma membrane" "HPA016586: AB_1852127, HPA077537: , HPA077773: " "unprognostic (6.68e-3)" "unprognostic (1.68e-1)" "unprognostic (2.99e-2)" "unprognostic (8.56e-6)" "unprognostic (1.04e-1)" "unprognostic (1.10e-1)" "unprognostic (1.88e-1)" "unprognostic (9.13e-3)" "unprognostic (4.86e-2)" "unprognostic (1.69e-1)" "unprognostic (5.04e-3)" "unprognostic (2.90e-2)" "unprognostic (1.63e-1)" "unprognostic (1.17e-1)" "unprognostic (3.89e-2)" "unprognostic (8.71e-5)" "unprognostic (1.72e-1)" 0.6 7.0 8.4 1.6 22.0 1.4 2.4 1.3 11.4 1.3 1.9 31.3 0.0 2.2 1.2 1.2 0.7 1.4 2.2 1.0 11.8 5.7 0.7 0.7 0.8 3.2 16.4 10.2 0.7 2.7 0.8 16.1 0.6 15.0 2.2 2.5 0.1 3.3 1.4 0.6 1.9 1.8 1.1 9.9 2.6 5.9 4.0 18.1 0.0 1.1 0.0 3.2 0.9 0.5 4.5 0.9 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.0 0.0 0.0 0.1 0.0 0.8 4.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 9.4 0.0 0.0 0.4 0.5 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.1 0.2 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 4.5 0.3 0.0 0.0 0.0 0.0 0.9 0.0 0.0 8.4 22.0 1.3 11.4 11.8 5.7 16.4 10.2 15.0 18.1 0.0 0.0 0.0 1.6 0.5 4.7 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 2.7 0.0 0.0 0.0 0.5 0.0 0.0 1.3 0.0 0.0 0.1 0.0 3.5 0.0 0.0 1.1 0.0 0.0 3.3 0.0 1.7 3.7 0.6 0.0 0.0 0.0 0.9 0.0 0.2 0.7 1.9 0.0 0.1 0.0 0.2 0.2 KCNN3 "hSK3, KCa2.3, SKCA3" ENSG00000143603 "Potassium calcium-activated channel subfamily N member 3" Q9UGI6 1 154697455-154870280 "FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels" "Ion transport, Transport" "Calmodulin-binding, Ion channel" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 26.7" "Cell type enhanced" "Detected in many" 16 "Alveolar cells type 1: 11.9;Ciliated cells: 32.1;Endothelial cells: 16.9" "Cancer enhanced" "Detected in many" "glioma: 5.8" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 5.8;memory B-cell: 4.8" "Group enriched" "Detected in many" 9 "B-cells: 4.8;granulocytes: 5.8;monocytes: 2.7" "Cell line enhanced" "Detected in some" "Daudi: 18.1;HMC-1: 12.5;Karpas-707: 31.0;RPMI-8226: 8.4;U-266/70: 29.9;U-698: 10.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA057127 Enhanced Approved Nucleoplasm NA NA Nucleoplasm "HPA057127: AB_2683345" "unprognostic (2.09e-1)" "unprognostic (2.91e-2)" "unprognostic (3.41e-2)" "unprognostic (1.04e-1)" "unprognostic (7.22e-2)" "unprognostic (4.06e-2)" "unprognostic (2.19e-2)" "unprognostic (2.03e-1)" "unprognostic (3.43e-2)" "unprognostic (9.51e-2)" "unprognostic (4.07e-3)" "unprognostic (4.89e-2)" "prognostic unfavorable (1.97e-4)" "unprognostic (1.71e-2)" "unprognostic (1.54e-1)" "unprognostic (6.93e-2)" "unprognostic (1.80e-2)" 1.7 2.5 20.6 6.5 21.7 1.0 1.8 5.7 26.7 9.3 9.1 12.4 1.1 5.4 12.6 1.7 3.5 10.3 3.1 4.0 21.6 8.0 3.5 1.0 3.1 5.8 12.0 10.9 2.1 1.0 1.5 2.6 0.7 13.3 3.4 4.6 0.1 2.7 2.7 8.5 1.1 3.9 10.6 8.1 5.0 4.4 1.3 15.5 0.2 3.7 3.5 9.2 8.3 4.9 4.8 0.4 5.8 2.7 0.0 0.0 0.4 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 18.1 1.4 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 12.5 0.2 0.0 0.1 0.0 0.0 0.4 0.0 0.0 31.0 0.3 0.0 0.1 0.0 0.4 0.0 1.2 0.0 7.7 8.4 0.0 0.0 0.4 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.5 0.5 0.0 0.0 0.0 29.9 3.9 10.0 0.3 0.0 2.9 5.8 0.0 0.0 0.0 0.2 0.0 4.8 0.0 0.0 0.4 1.1 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.4 20.6 21.7 5.7 10.3 21.6 8.0 12.0 10.9 13.3 15.5 11.9 2.4 0.0 0.5 1.1 0.2 2.2 0.0 32.1 3.4 0.0 2.0 0.0 3.3 0.2 2.6 16.9 0.0 0.0 0.2 0.0 2.3 0.4 0.0 0.0 0.4 0.0 4.1 5.5 0.0 6.2 0.3 0.8 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.3 0.0 1.0 0.5 0.1 1.5 0.0 0.0 0.0 0.1 KIAA1211L "C2orf55, MGC42367" ENSG00000196872 "KIAA1211 like" Q6NV74 2 98793846-98936259 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 27.4;epididymis: 27.7" "Cell type enhanced" "Detected in many" 15 "Ciliated cells: 95.0" "Low cancer specificity" "Detected in all" "Group enriched" "Detected in many" 6 "amygdala: 19.0;basal ganglia: 23.7;cerebral cortex: 27.4;hippocampal formation: 12.9;olfactory region: 18.3" "Cell type enhanced" "Detected in single" "neutrophil: 1.4" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "BEWO: 22.3;HDLM-2: 32.0;Karpas-707: 9.4;MCF7: 8.5;SiHa: 9.1;SK-BR-3: 12.2" "Group enriched" "Detected in many" 15 "amygdala: 29.7;basal ganglia: 59.8;cerebral cortex: 52.5;hippocampal formation: 81.9;olfactory region: 36.3" "HPA051082, HPA061678" Enhanced Approved "Microtubules,Cytokinetic bridge,Centrosome" Yes No "Microtubules, Centrosome" "Cytokinetic bridge" "HPA051082: AB_2681337, HPA061678: AB_2684584" "unprognostic (3.56e-3)" "unprognostic (1.23e-3)" "unprognostic (5.88e-2)" "unprognostic (6.43e-2)" "unprognostic (1.34e-1)" "unprognostic (1.24e-1)" "unprognostic (3.67e-3)" "unprognostic (2.12e-1)" "unprognostic (5.10e-2)" "unprognostic (7.65e-2)" "unprognostic (3.23e-2)" "unprognostic (3.61e-2)" "prognostic favorable (1.13e-5)" "unprognostic (1.22e-1)" "unprognostic (3.34e-1)" "prognostic favorable (1.33e-5)" "unprognostic (2.22e-2)" 2.7 0.8 19.0 1.3 23.7 0.5 3.5 2.4 27.4 4.6 5.0 0.8 3.5 6.7 1.5 27.7 9.1 19.3 2.5 1.4 12.9 1.9 2.5 0.4 3.9 0.6 2.7 18.3 1.4 3.7 9.6 4.3 4.0 0.1 1.6 4.0 0.0 9.0 4.3 1.3 4.3 6.1 2.1 1.2 1.0 6.8 3.6 3.6 0.0 4.3 3.3 2.5 2.4 3.2 0.0 0.7 1.4 0.3 0.2 0.9 0.0 4.3 0.2 0.1 1.7 0.0 0.0 22.3 0.0 0.0 0.0 0.0 0.2 2.6 0.0 5.7 0.0 0.1 3.9 0.1 0.2 0.0 32.0 0.6 0.0 0.2 0.2 0.0 0.0 0.0 0.1 1.2 0.0 0.6 0.0 1.3 0.0 0.0 9.4 0.0 8.5 0.1 0.6 0.0 4.3 0.4 0.0 0.0 0.4 1.7 3.4 3.2 0.5 9.1 12.2 0.0 0.0 4.7 0.7 5.5 0.0 0.7 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.3 0.9 0.0 0.0 0.0 0.0 0.9 0.6 0.0 0.0 0.1 0.0 1.4 0.2 0.0 0.7 0.0 0.0 19.0 23.7 2.4 27.4 12.9 1.9 2.7 18.3 0.1 3.6 14.9 2.9 0.0 3.1 0.6 0.0 4.2 5.1 95.0 23.9 3.5 0.0 0.3 3.3 3.7 11.8 9.0 10.0 0.0 6.5 1.1 0.2 1.7 0.0 0.0 2.6 0.0 15.1 6.7 1.5 17.2 0.3 0.9 0.0 0.0 11.4 0.0 4.8 8.6 0.4 2.2 0.0 0.0 0.4 15.9 12.6 5.3 0.3 0.0 8.8 5.1 LAMP5 "BAD-LAMP, C20orf103, dJ1119D9.3, UNC-46" ENSG00000125869 "Lysosomal associated membrane protein family member 5" Q9UJQ1 20 9514358-9530524 "Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 42.1;brain: 105.2" "Cell type enriched" "Detected in some" 7 "Horizontal cells: 57.2" "Low cancer specificity" "Detected in all" "Region enriched" "Detected in all" 5 "basal ganglia: 105.2" "Cell type enriched" "Detected in some" 15 "plasmacytoid DC: 42.1" "Lineage enriched" "Detected in many" 30 "dendritic cells: 42.1" "Cell line enhanced" "Detected in some" "Karpas-707: 95.0;SH-SY5Y: 17.4;THP-1: 33.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA004802, HPA070765" Enhanced Uncertain "Mitotic spindle,Centriolar satellite,Cytosol" NA NA Cytosol "Mitotic spindle, Centriolar satellite" "HPA004802: AB_10603682, HPA070765: AB_2686309" "unprognostic (2.78e-2)" "unprognostic (3.90e-3)" "unprognostic (5.73e-4)" "unprognostic (5.47e-2)" "unprognostic (7.89e-2)" "unprognostic (2.67e-1)" "unprognostic (3.80e-3)" "unprognostic (1.45e-1)" "unprognostic (1.54e-2)" "unprognostic (1.91e-1)" "unprognostic (1.94e-1)" "unprognostic (1.95e-1)" "prognostic unfavorable (6.46e-6)" "unprognostic (5.12e-3)" "unprognostic (3.74e-2)" "unprognostic (1.08e-2)" "unprognostic (4.49e-3)" 0.5 4.1 21.6 1.5 105.2 2.0 1.0 2.3 28.6 9.1 1.3 0.6 1.8 1.3 4.6 6.0 0.6 9.7 2.9 0.6 18.7 4.1 0.9 0.5 1.1 4.8 4.5 7.7 21.2 1.3 0.3 2.0 0.4 23.2 2.3 1.4 2.6 1.4 3.6 0.3 0.5 1.4 3.8 6.7 1.4 1.6 1.1 4.8 0.0 1.1 0.0 4.7 1.2 0.6 1.4 42.1 0.9 0.5 0.0 0.0 0.7 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 95.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 17.4 0.0 0.0 0.0 0.1 0.0 33.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 0.9 0.5 0.0 0.0 0.1 0.0 1.4 0.0 0.0 2.8 0.1 0.0 0.0 0.1 0.0 0.0 42.1 0.0 0.7 21.6 105.2 2.3 19.1 18.7 4.1 4.5 7.7 23.2 4.8 0.0 1.4 2.2 0.0 0.1 7.5 0.2 0.0 0.0 0.0 0.0 7.9 0.0 0.0 0.6 5.8 0.1 0.0 0.0 0.0 0.0 0.6 0.8 0.0 0.0 1.1 57.2 0.0 0.0 1.2 5.6 0.6 0.2 3.3 8.2 0.0 4.0 0.2 0.0 0.0 0.0 4.9 0.0 1.4 0.2 0.1 0.0 0.0 0.0 0.0 0.0 MGARP "C4orf49, CESP-1, HUMMR, OSAP" ENSG00000137463 "Mitochondria localized glutamic acid rich protein" Q8TDB4 4 139266163-139280338 "Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adrenal gland: 88.9;retina: 30.7" "Group enriched" "Detected in some" 9 "Bipolar cells: 140.5;Horizontal cells: 197.0;Muller glia cells: 424.1" "Cancer enhanced" "Detected in some" "renal cancer: 4.1" "Group enriched" "Detected in many" 4 "basal ganglia: 4.5;cerebellum: 8.0" "Cell type enhanced" "Detected in some" "memory CD4 T-cell: 1.7;naive CD4 T-cell: 1.6" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "BJ: 10.7;fHDF/TERT166: 15.9;HHSteC: 12.9;HUVEC TERT2: 32.4" "Low region specificity" "Detected in some" "HPA015994, HPA070835" Enhanced Supported Mitochondria NA NA Mitochondria "HPA015994: AB_2630370, HPA070835: " "unprognostic (2.68e-1)" "unprognostic (1.73e-1)" "unprognostic (8.18e-2)" "unprognostic (4.25e-2)" "unprognostic (3.54e-2)" "unprognostic (3.11e-2)" "unprognostic (3.42e-2)" "unprognostic (1.02e-3)" "unprognostic (2.90e-2)" "unprognostic (4.96e-2)" "unprognostic (1.50e-2)" "unprognostic (1.31e-1)" "unprognostic (4.08e-2)" "unprognostic (1.47e-2)" "unprognostic (9.91e-2)" "unprognostic (2.09e-2)" "unprognostic (2.36e-1)" 3.2 88.9 1.0 0.5 4.5 0.4 1.2 8.0 1.2 3.6 1.0 2.1 1.1 0.4 2.6 3.0 0.5 0.8 1.3 6.1 0.8 1.4 1.0 0.4 0.5 0.6 1.0 0.0 20.1 0.5 0.4 15.3 0.5 1.5 2.0 0.5 30.7 0.4 2.0 0.6 0.5 0.4 2.3 0.7 0.6 0.4 5.9 0.5 0.0 0.5 0.0 0.5 2.1 1.0 0.5 0.0 0.0 0.3 0.5 1.7 0.3 0.0 0.5 0.3 0.2 0.8 0.4 0.0 10.7 0.0 1.6 0.0 0.0 0.1 0.0 0.1 15.9 4.6 0.2 2.3 0.0 0.9 0.0 1.0 0.0 0.0 0.1 12.9 0.1 0.1 3.9 0.3 1.7 0.1 3.8 32.4 0.1 0.2 0.2 2.6 0.0 0.4 0.2 0.6 0.2 0.0 0.0 0.0 0.0 0.3 0.1 0.3 0.6 0.0 0.0 0.1 0.2 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.4 0.3 0.3 4.5 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.5 1.7 0.4 0.0 0.3 1.6 0.7 0.0 0.5 0.2 0.0 0.3 0.3 1.0 4.5 8.0 1.2 0.8 1.4 1.0 0.0 1.5 0.5 0.0 0.0 0.0 0.7 1.4 140.5 2.5 0.0 0.0 0.0 0.0 7.9 0.2 1.7 0.0 0.2 0.2 0.0 0.0 0.0 0.1 2.4 0.3 0.0 0.0 0.5 197.0 0.0 0.6 0.0 0.0 15.8 0.0 0.0 0.0 0.0 424.1 0.1 0.0 23.3 7.6 28.7 0.0 0.4 0.7 0.3 0.6 0.2 0.0 0.0 0.3 NOS1 "nNOS, NOS" ENSG00000089250 "Nitric oxide synthase 1" P29475 12 117208142-117452170 "Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Oxidoreductase" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 6 "brain: 13.4;skeletal muscle: 36.3" "Cell type enhanced" "Detected in some" 12 "Basal glandular cells: 7.9;Basal keratinocytes: 3.4;Glandular cells: 2.8;Ito cells: 8.0" "Low cancer specificity" "Detected in some" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in some" "Low lineage specificity" "Detected in single" "Cell line enhanced" "Detected in some" "HaCaT: 6.3;RH-30: 13.1;RPTEC TERT1: 8.2;U-2 OS: 2.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002167, HPA058312, HPA069509" Enhanced Supported "Nucleoplasm,Plasma membrane" NA NA "Plasma membrane" Nucleoplasm "CAB002167: AB_564073, HPA058312: AB_2683676, HPA069509: " "unprognostic (1.63e-1)" "unprognostic (3.14e-2)" "unprognostic (2.18e-2)" "unprognostic (6.64e-3)" "unprognostic (4.91e-2)" "unprognostic (2.74e-1)" "unprognostic (2.54e-1)" "unprognostic (9.12e-3)" "unprognostic (2.51e-1)" "unprognostic (1.10e-1)" "unprognostic (1.07e-1)" "unprognostic (7.56e-2)" "unprognostic (1.01e-1)" "unprognostic (3.73e-2)" "unprognostic (1.34e-1)" "unprognostic (5.97e-4)" "unprognostic (1.87e-1)" 0.5 0.6 3.8 3.5 13.4 0.7 0.6 4.4 4.8 0.7 2.0 1.1 0.0 0.5 0.6 0.7 1.3 0.8 0.5 0.5 2.8 4.4 1.9 0.5 1.4 0.6 2.4 1.6 0.5 1.9 0.4 0.8 0.4 5.9 1.6 0.9 0.6 3.8 0.6 36.3 2.2 0.6 0.8 1.2 0.5 0.5 0.9 3.0 0.0 0.6 0.0 0.5 0.9 0.6 0.9 0.6 2.1 0.5 0.8 0.5 0.0 0.0 0.4 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.3 0.0 0.0 6.3 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.2 0.0 1.5 0.0 13.1 0.1 8.2 0.1 0.3 1.3 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 2.5 0.0 0.0 0.1 0.0 0.1 0.4 0.1 0.0 2.1 0.5 0.5 0.5 0.4 0.4 0.7 0.4 0.3 0.2 0.9 0.5 0.5 1.9 0.8 0.5 0.6 0.3 0.0 3.8 13.4 4.4 4.8 2.8 4.4 2.4 1.6 5.9 3.0 0.0 0.0 0.0 7.9 3.4 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 1.9 0.4 0.0 0.0 0.0 0.0 0.1 2.8 0.0 0.0 0.0 0.0 0.0 8.0 0.0 0.2 0.3 0.2 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.9 0.5 0.0 0.0 0.0 1.0 PCDH11X "PCDH-X, PCDH11, PCDHX, PPP1R119" ENSG00000102290 "Protocadherin 11 X-linked" Q9BZA7 X 91779261-92623230 "Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 5 "brain: 7.0;ovary: 12.6;parathyroid gland: 5.2" "Cell type enhanced" "Detected in many" 12 "Cytotrophoblasts: 16.9;Horizontal cells: 31.8;Syncytiotrophoblasts: 13.2" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 4.3;AN3-CA: 6.5;NTERA-2: 1.1;SuSa: 1.9;THP-1: 1.1" HPA077495 Approved NA NA "HPA077495: " "unprognostic (4.22e-3)" "unprognostic (1.16e-1)" "unprognostic (1.39e-4)" "unprognostic (1.18e-1)" "unprognostic (8.20e-3)" "unprognostic (6.32e-2)" "unprognostic (9.10e-2)" "unprognostic (6.19e-2)" "unprognostic (4.58e-1)" "unprognostic (1.58e-1)" "unprognostic (2.45e-2)" "unprognostic (3.86e-1)" 0.0 0.3 2.6 0.1 7.0 0.0 0.2 0.0 4.8 1.7 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.8 4.2 0.0 0.0 0.0 0.2 1.3 12.6 0.0 5.2 0.3 1.2 0.0 0.0 0.0 0.4 0.0 0.1 0.0 0.3 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.3 6.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 1.1 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.9 9.0 0.0 0.3 1.3 3.5 0.6 0.0 1.4 5.7 0.0 0.0 16.9 0.0 0.0 0.4 0.7 0.0 0.0 0.0 0.2 0.8 0.2 1.1 0.4 0.9 31.8 0.0 1.3 0.0 0.0 8.9 1.4 10.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0 1.3 6.5 1.0 0.0 0.9 0.6 13.2 0.0 0.0 0.4 PCDHGC5 PCDH-GAMMA-C5 ENSG00000240764 "Protocadherin gamma subfamily C, 5" Q9Y5F6 5 141489121-141512979 "Predicted membrane proteins" "Cell adhesion" "Evidence at protein level" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 15 "brain: 43.7" "Not detected" "Not detected" "Group enriched" "Detected in some" 13 "glioma: 3.1;head and neck cancer: 0.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "hTERT-RPE1: 5.0;SuSa: 8.4;U-138 MG: 16.0;U-251 MG: 6.8;U-87 MG: 9.8" "Group enriched" "Detected in many" 5 "amygdala: 129.6;basal ganglia: 118.6;cerebral cortex: 130.2;hippocampal formation: 113.0;olfactory region: 85.4" "HPA008755, HPA010580, HPA076140" Supported Uncertain "Nucleoplasm,Vesicles,Plasma membrane,Cytosol" NA NA "Vesicles, Plasma membrane" "Nucleoplasm, Cytosol" "HPA008755: AB_1079577, HPA010580: AB_2732401, HPA076140: " "unprognostic (2.86e-3)" "unprognostic (7.63e-4)" "unprognostic (2.00e-1)" "unprognostic (3.52e-3)" "unprognostic (5.42e-2)" "unprognostic (1.14e-1)" "unprognostic (5.65e-2)" "unprognostic (2.38e-2)" "unprognostic (2.14e-1)" "unprognostic (3.16e-2)" "unprognostic (3.90e-1)" "unprognostic (1.66e-2)" "unprognostic (1.01e-9)" "unprognostic (6.87e-3)" "unprognostic (3.89e-2)" "unprognostic (3.13e-1)" "unprognostic (3.77e-3)" 1.0 1.1 7.4 1.1 34.5 0.9 1.1 3.0 43.7 1.1 1.0 2.8 0.0 0.9 1.4 1.3 1.0 1.2 1.2 2.8 11.8 2.8 0.9 0.9 1.1 0.9 2.2 10.0 1.1 1.0 1.0 1.1 1.0 2.3 1.3 1.0 0.0 0.9 1.6 1.6 1.5 0.9 2.0 0.8 1.0 1.0 1.3 1.1 0.0 1.0 0.0 1.0 1.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.3 0.4 1.7 0.2 0.8 0.6 0.5 0.6 0.0 0.0 0.5 1.6 2.4 0.1 0.1 0.0 0.4 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 3.5 0.0 5.0 0.0 0.0 0.0 0.0 1.1 0.1 0.0 0.0 0.0 0.0 0.9 0.8 0.3 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 8.4 0.1 0.2 0.1 16.0 0.2 0.2 6.8 0.0 0.0 0.0 9.8 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.4 34.5 3.0 39.2 11.8 2.8 2.2 10.0 2.3 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PCP4L1 IQM1 ENSG00000248485 "Purkinje cell protein 4 like 1" A6NKN8 1 161258727-161285450 "Predicted intracellular proteins" "Evidence at protein level" "Evidence at protein level" "No human protein/transcript evidence" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 67.7;urinary bladder: 33.2" "Cell type enhanced" "Detected in many" 13 "Basal glandular cells: 23.9;Bipolar cells: 34.5;Sertoli cells: 19.4;Urothelial cells: 42.7" "Group enriched" "Detected in many" 6 "cervical cancer: 12.4;head and neck cancer: 5.1;lung cancer: 13.6;testis cancer: 18.9;urothelial cancer: 21.8" "Group enriched" "Detected in all" 5 "basal ganglia: 67.7;cerebral cortex: 17.9;pons and medulla: 30.8" "Cell type enhanced" "Detected in single" "T-reg: 3.1" "Lineage enhanced" "Detected in single" "T-cells: 3.1" "Group enriched" "Detected in some" 6 "RT4: 16.1;T-47d: 10.5" "Low region specificity" "Detected in all" HPA052833 Enhanced Supported Approved Nucleoplasm,Mitochondria NA NA "Nucleoplasm, Mitochondria" "HPA052833: AB_2681968" "unprognostic (1.81e-2)" "unprognostic (9.39e-2)" "unprognostic (5.25e-2)" "unprognostic (2.07e-1)" "unprognostic (3.03e-2)" "unprognostic (1.87e-2)" "unprognostic (2.51e-1)" "prognostic favorable (8.10e-5)" "unprognostic (2.39e-1)" "unprognostic (1.92e-1)" "unprognostic (4.93e-2)" "unprognostic (7.37e-2)" "unprognostic (3.63e-5)" "unprognostic (4.81e-2)" "unprognostic (1.25e-1)" "unprognostic (2.09e-1)" "unprognostic (6.15e-2)" 3.2 1.0 5.7 1.3 67.7 0.6 2.2 4.4 28.9 4.3 4.3 1.4 1.5 2.2 2.2 3.3 16.5 2.1 3.9 1.3 3.9 6.3 1.0 4.3 5.0 0.7 7.8 4.6 2.6 0.5 0.6 21.9 0.9 30.8 5.5 3.2 5.9 1.2 17.8 1.0 2.8 3.3 6.8 7.5 0.8 1.2 2.3 5.3 0.0 1.0 0.0 3.0 33.2 4.1 0.0 0.7 0.0 0.0 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 2.0 0.0 0.0 0.1 0.0 0.0 0.0 2.2 0.4 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.0 0.1 0.0 0.1 0.0 16.1 2.2 0.0 0.0 0.3 0.0 0.2 10.5 0.4 0.2 0.0 0.0 0.0 0.0 1.0 1.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 5.7 67.7 4.4 17.9 3.9 6.3 7.8 4.6 30.8 5.3 3.0 5.4 0.0 23.9 0.0 34.5 0.2 0.0 0.0 7.9 0.0 5.9 0.3 0.0 0.0 0.0 0.0 0.0 0.0 1.2 1.6 0.2 1.8 1.1 0.9 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.2 0.0 1.8 0.0 4.1 19.4 9.5 0.2 0.2 0.3 1.5 0.0 0.0 42.7 PCSK1N "BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII" ENSG00000102109 "Proprotein convertase subtilisin/kexin type 1 inhibitor" Q9UHG2 X 48831094-48835633 "Predicted secreted proteins" Neuropeptide "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 74.9;kidney: 72.9;pituitary gland: 127.7" "Group enriched" "Detected in many" 5 "Intestinal endocrine cells: 2932.5;Proximal tubular cells: 1024.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "MAIT T-cell: 3.0;memory CD4 T-cell: 6.5;memory CD8 T-cell: 6.3;naive CD4 T-cell: 2.7;naive CD8 T-cell: 8.2;T-reg: 2.1" "Lineage enriched" "Detected in single" 77 "T-cells: 8.2" "Cell line enhanced" "Detected in some" "HEK 293: 20.0;PC-3: 50.7;SCLC-21H: 20.1;SH-SY5Y: 18.6;SiHa: 17.6;U-266/84: 23.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA003925, HPA064734" Enhanced Supported Approved Vesicles "Secreted to blood" NA NA 5300000 Vesicles "HPA003925: AB_1079582, HPA064734: AB_2685339" "unprognostic (2.44e-3)" "unprognostic (5.86e-2)" "unprognostic (1.94e-1)" "prognostic unfavorable (1.15e-4)" "unprognostic (3.36e-1)" "unprognostic (4.76e-3)" "unprognostic (1.49e-2)" "unprognostic (3.34e-1)" "unprognostic (5.63e-2)" "unprognostic (3.55e-1)" "unprognostic (1.50e-3)" "unprognostic (2.79e-3)" "prognostic favorable (1.36e-4)" "unprognostic (3.34e-2)" "unprognostic (2.91e-2)" "unprognostic (1.91e-1)" "unprognostic (2.14e-1)" 4.1 27.5 49.1 2.6 72.7 2.1 2.2 15.6 70.3 3.2 9.8 10.8 1.5 12.4 4.4 10.9 2.1 2.3 2.8 2.7 38.5 74.9 72.9 2.1 2.6 2.2 33.5 29.0 2.2 20.0 12.4 127.7 2.3 32.9 4.6 2.7 6.6 2.8 3.1 2.2 2.8 8.5 2.7 18.3 2.4 26.0 3.8 9.8 0.0 2.2 0.0 2.1 2.1 0.5 0.1 0.0 0.0 0.0 0.0 8.2 0.8 0.0 1.8 0.0 5.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 1.8 0.0 0.0 3.6 0.0 1.4 0.2 0.0 0.3 0.0 0.0 20.0 0.0 0.0 3.0 0.0 0.0 1.2 0.0 0.2 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.1 2.7 0.0 50.7 0.0 0.0 0.1 0.4 0.0 20.1 18.6 17.6 0.0 1.4 0.2 0.0 0.0 0.0 0.0 7.8 0.0 1.6 4.6 23.4 0.1 0.1 0.0 0.5 0.0 0.0 0.0 1.1 0.0 3.0 0.0 6.5 6.3 0.0 0.1 2.7 8.2 0.0 0.0 0.0 0.0 2.1 0.8 49.1 72.7 15.6 70.3 38.5 74.9 33.5 29.0 32.9 9.8 0.0 0.0 2.2 1.5 14.1 134.7 1.0 5.1 1.4 0.0 369.9 49.1 0.5 235.4 7.5 11.6 0.5 12.9 0.0 0.6 43.5 6.2 36.6 0.0 0.0 1.5 413.2 2932.5 0.0 0.0 41.9 3.1 2.7 54.0 0.0 16.6 54.9 36.6 411.7 6.7 1024.2 101.7 0.0 16.5 18.2 20.6 10.0 1.6 3.2 10.1 2.6 PDE1B PDES1B ENSG00000123360 "Phosphodiesterase 1B" Q01064 12 54549350-54579239 "Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins" "Calmodulin-binding, Hydrolase" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 4 "brain: 52.6" "Cell type enhanced" "Detected in many" 11 "Erythroid cells: 23.3;Kupffer cells: 11.5;Sertoli cells: 12.9;Smooth muscle cells: 9.5" "Low cancer specificity" "Detected in many" "Region enhanced" "Detected in all" "basal ganglia: 52.6" "Cell type enriched" "Detected in single" 4 "naive CD4 T-cell: 1.6" "Lineage enriched" "Detected in single" 4 "T-cells: 1.6" "Cell line enhanced" "Detected in some" "HDLM-2: 11.5;HL-60: 6.4;HMC-1: 12.3;NB-4: 8.1;THP-1: 7.8;U-937: 6.5" "Region enriched" "Detected in all" 6 "basal ganglia: 895.2" "Region enriched" "Detected in all" 7 "basal ganglia: 253.8" HPA018492 Enhanced NA NA "HPA018492: AB_1855119" "unprognostic (2.90e-1)" "unprognostic (1.51e-1)" "unprognostic (7.67e-4)" "unprognostic (5.63e-3)" "unprognostic (7.02e-2)" "unprognostic (7.51e-2)" "unprognostic (1.97e-1)" "unprognostic (9.39e-2)" "unprognostic (1.14e-1)" "unprognostic (5.11e-2)" "unprognostic (3.84e-3)" "unprognostic (2.70e-2)" "prognostic unfavorable (4.77e-6)" "unprognostic (6.64e-4)" "unprognostic (2.14e-1)" "unprognostic (3.09e-1)" "unprognostic (2.83e-2)" 12.3 1.4 9.9 4.6 52.6 5.6 2.7 3.1 19.4 2.6 3.7 1.4 0.0 1.2 3.9 2.5 1.7 2.4 2.9 1.9 3.7 3.8 1.3 1.6 2.9 1.6 3.0 9.3 12.5 0.6 11.0 0.5 0.5 5.8 1.0 1.7 0.5 1.3 2.1 0.7 1.0 2.6 4.9 1.2 4.8 2.5 1.1 7.7 0.0 2.7 0.0 1.1 2.8 1.1 0.2 0.3 0.1 0.3 0.1 1.6 0.4 0.0 0.0 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 3.1 0.1 0.0 0.0 0.0 1.8 0.0 0.0 11.5 0.3 4.7 0.0 0.0 0.0 6.4 12.3 0.7 0.0 0.0 0.0 0.0 0.0 4.6 0.0 1.9 0.0 0.0 0.7 8.1 3.4 0.0 0.0 2.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 7.8 0.0 0.0 0.2 0.0 0.0 0.0 0.1 2.4 0.0 6.5 1.3 0.0 0.3 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.3 0.2 1.6 0.0 0.1 0.1 0.0 0.0 0.0 0.4 9.9 52.6 3.1 19.4 3.7 3.8 3.0 9.3 5.8 7.7 0.0 0.6 0.0 0.2 0.9 0.1 3.1 0.0 0.0 1.2 3.5 0.0 0.0 0.0 0.0 4.8 0.3 0.0 23.3 0.0 0.0 0.4 0.3 0.0 0.0 7.3 4.8 1.7 0.0 11.5 3.4 2.0 5.2 0.0 1.8 0.0 0.0 0.0 0.0 2.8 0.0 0.1 12.9 9.5 0.9 0.5 0.4 0.2 1.5 0.0 0.1 PDYN "ADCA, PENKB, SCA23" ENSG00000101327 Prodynorphin P01213 20 1978757-1994285 "Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters" "Endorphin, Neuropeptide, Neurotransmitter, Opioid peptide" "Disease mutation, Neurodegeneration, Spinocerebellar ataxia" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 17 "brain: 55.9" "Group enriched" "Detected in some" 102 "Early spermatids: 39.7;Late spermatids: 87.7" "Group enriched" "Detected in some" 29 "glioma: 2.6;ovarian cancer: 1.6" "Region enriched" "Detected in many" 4 "basal ganglia: 55.9" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "AF22: 1.6;NTERA-2: 2.8;THP-1: 2.7" "Group enriched" "Detected in many" 4 "basal ganglia: 150.7;hypothalamus: 70.9" "Region enhanced" "Detected in many" "basal ganglia: 131.1" "HPA053342, CAB079777" Enhanced Supported "Secreted in brain" NA NA "CAB079777: , HPA053342: AB_2682121" "unprognostic (7.00e-2)" "unprognostic (1.07e-1)" "unprognostic (1.40e-1)" "unprognostic (3.73e-2)" 0.4 0.4 13.2 0.4 55.9 0.4 0.4 0.0 40.3 0.4 0.4 1.2 0.0 0.4 0.4 0.4 0.4 0.4 0.4 0.4 5.0 3.9 0.4 0.4 0.4 0.4 0.7 3.7 0.4 0.4 0.4 0.0 0.4 0.2 0.4 0.4 0.0 0.4 0.4 0.4 0.6 0.4 0.4 2.2 0.4 0.4 3.2 1.1 0.0 0.5 0.0 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.2 55.9 0.0 3.8 5.0 3.9 0.7 3.7 0.2 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 39.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 87.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.0 PRLH PRH ENSG00000071677 "Prolactin releasing hormone" P81277 2 237566574-237567175 "Predicted secreted proteins" Hormone "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 8.1;heart muscle: 4.5" "Not detected" "Not detected" "Cancer enhanced" "Detected in single" "endometrial cancer: 0.7" "Not detected" "Not detected" "Not detected" "Not detected" "Cell line enhanced" "Detected in some" "A549: 6.0;MCF7: 4.4;RPMI-8226: 3.7;SK-BR-3: 1.8;T-47d: 2.1;U-87 MG: 2.4" "Group enriched" "Detected in some" 58 "hypothalamus: 13.4;pons and medulla: 22.5" "Region enriched" "Detected in single" 13 "pons and medulla: 5.1" HPA014976 Approved "Secreted - unknown location" NA NA "HPA014976: AB_2732413" "unprognostic (8.28e-4)" "unprognostic (3.22e-2)" "unprognostic (5.42e-2)" 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 4.5 0.0 0.6 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.1 0.0 1.1 0.0 0.0 0.0 0.0 0.0 8.1 0.0 0.3 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 1.8 0.4 0.0 2.1 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 PTPRN "IA-2, ICA512" ENSG00000054356 "Protein tyrosine phosphatase, receptor type N" Q16849 2 219289623-219309648 "Disease related genes, Predicted intracellular proteins, Predicted membrane proteins" "Transcription, Transcription regulation" Receptor "Diabetes mellitus" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 89.6;pancreas: 28.9;pituitary gland: 43.4" "Group enriched" "Detected in some" 13 "Bipolar cells: 48.9;Cone photoreceptor cells: 56.9;Horizontal cells: 92.2;Intestinal endocrine cells: 45.2;Rod photoreceptor cells: 31.1" "Group enriched" "Detected in some" 12 "glioma: 5.3;pancreatic cancer: 18.4" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 8 "U-2 OS: 20.3;U-87 MG: 75.5" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA007152, HPA007179" Enhanced Approved "Endoplasmic reticulum" NA NA "Endoplasmic reticulum" "HPA007152: AB_2667759, HPA007179: AB_1079714" "unprognostic (1.43e-1)" "unprognostic (1.33e-4)" "unprognostic (2.91e-3)" "unprognostic (5.83e-3)" "prognostic unfavorable (1.45e-7)" "unprognostic (3.64e-2)" "unprognostic (1.24e-4)" "unprognostic (1.58e-3)" "unprognostic (1.02e-1)" "unprognostic (6.20e-4)" "unprognostic (1.44e-2)" "unprognostic (1.54e-1)" "unprognostic (2.28e-10)" "unprognostic (1.43e-2)" "unprognostic (2.49e-1)" "unprognostic (1.10e-2)" "unprognostic (8.61e-2)" 1.7 22.3 19.3 4.7 35.7 1.7 1.3 17.3 89.6 1.2 2.4 2.5 0.0 2.5 1.5 1.2 1.5 1.3 1.5 1.4 21.6 40.1 1.5 1.2 1.4 1.3 14.4 19.8 1.3 28.9 1.2 43.4 1.4 22.0 1.4 1.9 3.1 1.2 1.3 1.2 2.0 2.5 2.4 3.5 1.3 6.0 1.4 2.1 0.0 1.5 0.0 1.2 2.7 0.0 0.1 0.3 0.2 0.0 0.0 0.6 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.0 0.0 0.0 0.0 0.3 1.3 2.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.6 0.0 0.1 2.5 0.0 6.2 0.0 0.0 0.0 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 3.2 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 20.3 0.0 0.0 0.0 0.0 0.2 75.5 0.0 0.3 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.3 0.1 0.0 0.4 0.2 0.0 0.0 0.0 0.6 3.7 19.3 35.7 17.3 54.0 21.6 40.1 14.4 19.8 22.0 2.1 0.0 0.0 0.0 0.1 0.1 48.9 1.7 0.0 0.0 0.0 0.0 56.9 0.0 1.7 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.0 0.0 0.1 92.2 45.2 0.0 0.0 0.2 0.3 0.0 1.7 0.0 0.0 4.1 4.3 0.0 0.0 0.0 31.1 0.0 0.3 2.2 2.3 0.1 0.0 0.0 0.0 0.0 PTPRZ1 "phosphacan, PTP18, PTPRZ, PTPZ, RPTPB" ENSG00000106278 "Protein tyrosine phosphatase, receptor type Z1" P23471 7 121873089-122062036 "Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins" "Hydrolase, Protein phosphatase" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in many" 6 "brain: 118.1" "Cell type enhanced" "Detected in some" 17 "Club cells: 27.3;Horizontal cells: 62.0;Muller glia cells: 107.0" "Cancer enriched" "Detected in many" 14 "glioma: 175.5" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 9 "AF22: 94.3;NTERA-2: 26.3;WM-115: 41.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA015103 Enhanced Approved Vesicles,Cytosol "Secreted in brain" NA NA 950000 Cytosol Vesicles "HPA015103: AB_1855946" "unprognostic (8.49e-4)" "unprognostic (3.96e-3)" "unprognostic (4.11e-2)" "unprognostic (1.37e-1)" "unprognostic (9.18e-2)" "unprognostic (2.41e-2)" "unprognostic (8.30e-3)" "unprognostic (3.78e-2)" "unprognostic (1.57e-1)" "unprognostic (2.53e-1)" "unprognostic (9.17e-4)" "unprognostic (1.83e-1)" "unprognostic (8.72e-6)" "unprognostic (2.00e-1)" "unprognostic (2.16e-1)" "unprognostic (8.77e-2)" "prognostic unfavorable (9.36e-4)" 2.0 2.5 33.1 2.3 44.1 1.5 4.0 15.4 118.1 2.4 2.2 19.3 0.0 1.9 1.6 2.0 7.0 1.7 1.9 2.0 39.6 15.9 1.6 1.6 2.1 1.5 18.6 17.8 2.0 3.3 1.5 1.6 1.6 67.6 2.1 2.3 0.8 2.4 2.0 1.5 19.3 1.9 2.4 76.6 2.1 9.8 1.7 23.6 0.0 1.5 1.8 3.0 2.2 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 94.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 5.9 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 26.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.4 1.1 0.0 0.1 0.0 41.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 33.1 44.1 15.4 39.6 39.6 15.9 18.6 17.8 67.6 23.6 0.0 1.0 0.0 5.6 22.3 14.1 0.8 0.0 17.4 27.3 0.0 3.9 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.6 0.1 1.1 1.1 0.0 0.0 0.1 62.0 0.0 0.0 0.0 0.4 0.3 0.0 18.6 0.0 0.0 107.0 0.6 0.0 0.0 0.0 6.2 0.0 0.4 0.0 0.2 18.7 0.2 0.0 0.0 7.4 RTP5 "C2orf85, CXXC11, FLJ33590, Z3CXXC5" ENSG00000188011 "Receptor transporter protein 5 (putative)" Q14D33 2 241869600-241873823 "Predicted membrane proteins" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 18 "brain: 44.8" "Cell type enriched" "Detected in some" 7 "Early spermatids: 7.7" "Cancer enriched" "Detected in single" 10 "glioma: 1.7" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 23 "MOLT-4: 3.7;SCLC-21H: 7.4" HPA050902 Enhanced NA NA "HPA050902: AB_2681268" "unprognostic (3.26e-2)" "unprognostic (5.38e-4)" "unprognostic (2.43e-2)" "unprognostic (1.15e-1)" "unprognostic (3.01e-1)" "unprognostic (9.40e-4)" "unprognostic (8.68e-3)" "unprognostic (2.04e-1)" "unprognostic (6.34e-4)" "unprognostic (3.30e-1)" "unprognostic (9.01e-3)" "unprognostic (3.91e-1)" "unprognostic (9.08e-8)" "unprognostic (1.81e-1)" "unprognostic (1.77e-1)" "unprognostic (2.68e-2)" "unprognostic (3.72e-2)" 0.8 0.8 27.9 1.1 44.8 1.9 0.7 0.2 13.5 0.7 0.7 2.1 0.0 0.9 0.7 0.7 0.7 0.7 0.8 0.8 32.9 24.9 0.7 0.7 0.8 2.4 3.1 4.8 0.7 0.9 0.7 0.0 0.7 7.3 0.7 0.7 0.0 0.9 0.7 0.7 0.7 0.7 0.7 2.1 1.1 0.8 0.7 1.5 0.0 0.7 0.0 1.1 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 7.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.9 44.8 0.2 12.7 32.9 24.9 3.1 4.8 7.3 1.5 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 RYR1 "CCO, MHS, MHS1, PPP1R137, RYR" ENSG00000196218 "Ryanodine receptor 1" P21817 19 38433699-38587564 "Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters" "Calcium transport, Ion transport, Transport" "Calcium channel, Calmodulin-binding, Developmental protein, Ion channel, Ligand-gated ion channel, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "skeletal muscle: 231.0" "Cell type enriched" "Detected in many" 5 "Muller glia cells: 46.0" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 6 "intermediate monocyte: 3.2;myeloid DC: 5.3;non-classical monocyte: 6.3" "Group enriched" "Detected in many" 7 "dendritic cells: 5.3;monocytes: 6.3" "Cell line enhanced" "Detected in some" "A549: 5.7;HaCaT: 14.0;hTCEpi: 5.7;RH-30: 11.5;SiHa: 22.8;U-2 OS: 9.6" "Low region specificity" "Detected in some" HPA056416 Enhanced Approved "Golgi apparatus,Vesicles,Cytosol" NA NA "Golgi apparatus, Vesicles" Cytosol "HPA056416: AB_2683121" "unprognostic (2.22e-3)" "unprognostic (1.91e-3)" "unprognostic (9.59e-2)" "unprognostic (5.34e-4)" "unprognostic (2.50e-1)" "unprognostic (6.00e-2)" "unprognostic (2.11e-1)" "unprognostic (1.06e-1)" "unprognostic (1.18e-1)" "unprognostic (3.20e-3)" "unprognostic (3.52e-1)" "unprognostic (2.35e-1)" "unprognostic (1.07e-5)" "unprognostic (1.13e-2)" "unprognostic (8.10e-2)" "unprognostic (6.62e-3)" "unprognostic (1.34e-1)" 5.3 0.7 3.0 0.6 1.9 0.4 0.6 2.7 1.7 0.6 0.4 2.7 0.0 0.4 0.4 6.7 3.0 0.6 0.5 0.4 1.8 4.0 0.5 0.4 0.7 0.6 1.5 1.3 0.4 0.4 0.3 0.3 0.6 1.9 0.9 0.4 0.4 2.2 0.6 231.0 2.4 0.5 0.4 1.1 0.6 0.5 1.6 1.9 0.0 1.6 55.1 3.2 0.6 0.5 0.7 5.3 0.1 6.3 0.0 0.6 0.6 0.0 5.7 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 2.0 0.3 0.3 4.8 0.0 0.0 14.0 0.2 0.0 0.0 0.0 0.3 1.0 0.0 0.0 0.0 0.0 0.4 1.3 5.7 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.4 0.7 0.0 0.0 11.5 1.1 0.6 0.0 0.0 1.1 22.8 0.0 0.0 0.4 0.5 4.3 0.0 0.0 9.6 0.2 0.0 0.3 1.0 0.3 0.1 0.0 0.0 0.0 0.6 0.0 0.4 3.2 0.5 0.4 0.3 0.6 5.3 0.7 0.0 0.0 0.1 0.0 6.3 0.0 0.6 0.6 3.0 1.9 2.7 1.7 1.8 4.0 1.5 1.3 1.9 1.9 0.0 0.6 0.0 3.4 10.1 4.1 3.4 0.0 0.0 0.0 0.0 2.0 0.1 5.0 0.1 5.2 0.0 0.0 0.0 0.0 0.2 0.3 0.6 0.0 0.0 7.1 1.6 0.0 0.6 1.9 4.7 2.8 4.5 0.0 0.0 0.0 46.0 0.0 0.0 1.8 0.0 1.5 0.0 0.3 5.5 6.9 4.1 0.2 0.0 0.0 0.1 SLC18A2 "SVAT, SVMT, VMAT2" ENSG00000165646 "Solute carrier family 18 member A2" Q05940 10 117241073-117279430 "FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Transport" "Disease mutation, Dystonia, FDA approved drug targets, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "blood: 26.3;brain: 28.3;cervix, uterine: 31.2" "Cell type enriched" "Detected in some" 22 "granulocytes: 603.6" "Low cancer specificity" "Detected in some" "Group enriched" "Detected in many" 10 "hypothalamus: 9.0;midbrain: 28.3;pons and medulla: 26.5" "Cell type enriched" "Detected in some" 13 "basophil: 26.3" "Lineage enriched" "Detected in many" 13 "granulocytes: 26.3" "Cell line enriched" "Detected in some" 20 "HMC-1: 91.2" "Region enhanced" "Detected in many" "midbrain: 75.4" "Group enriched" "Detected in all" 5 "midbrain: 143.8;pons and medulla: 34.7" HPA073224 Enhanced Approved Vesicles,Centrosome NA NA "Vesicles, Centrosome" "HPA073224: AB_2732222" "unprognostic (1.49e-1)" "unprognostic (2.48e-1)" "unprognostic (2.33e-3)" "unprognostic (9.00e-2)" "unprognostic (2.85e-1)" "unprognostic (5.33e-3)" "unprognostic (2.23e-1)" "unprognostic (1.71e-2)" "unprognostic (1.40e-1)" "unprognostic (4.55e-2)" "unprognostic (2.00e-1)" "unprognostic (6.06e-3)" "unprognostic (7.94e-5)" "unprognostic (2.95e-2)" "unprognostic (2.31e-1)" "unprognostic (2.43e-1)" "unprognostic (3.57e-2)" 1.7 13.9 1.7 3.1 2.0 2.0 2.0 1.7 1.6 31.2 2.3 0.5 2.2 1.5 11.2 4.9 3.0 1.1 15.9 1.0 1.9 9.0 1.1 3.3 7.6 1.5 28.3 0.2 9.7 3.7 0.5 1.6 2.1 26.5 10.8 3.4 3.1 1.0 4.0 1.1 5.8 2.5 5.4 2.9 0.5 3.5 1.5 0.3 14.1 0.6 3.4 2.9 3.1 5.4 0.0 2.0 26.3 0.0 0.0 0.3 1.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 4.6 0.0 0.0 0.0 0.2 91.2 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.2 0.1 0.1 0.0 0.1 0.4 0.0 26.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.2 0.0 0.0 2.0 0.0 1.1 1.7 2.0 1.7 1.6 1.9 9.0 28.3 0.2 26.5 0.3 8.9 27.6 0.0 0.0 1.6 0.6 0.2 0.0 1.4 4.5 0.0 3.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 4.4 603.6 0.0 0.7 0.0 8.5 11.6 1.8 0.0 0.6 0.6 1.7 0.0 0.0 0.3 0.1 0.0 4.6 0.0 0.7 0.0 0.2 0.2 0.1 2.4 0.0 0.0 0.0 0.0 SLC6A3 "DAT, DAT1" ENSG00000142319 "Solute carrier family 6 member 3" Q01959 5 1392790-1445430 "Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters" "Neurotransmitter transport, Symport, Transport" "Disease mutation, Dystonia, FDA approved drug targets, Neurodegeneration, Parkinsonism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 14 "brain: 48.4" "Cell type enriched" "Detected in single" 5 "Alveolar cells type 2: 2.9" "Cancer enriched" "Detected in some" 18 "renal cancer: 25.7" "Region enriched" "Detected in some" 47 "midbrain: 48.4" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 5 "NTERA-2: 1.2;RPMI-8226: 2.1;SCLC-21H: 3.8" "Group enriched" "Detected in some" 8 "midbrain: 96.4;thalamus: 31.8" "Region enriched" "Detected in single" 138 "midbrain: 362.2" "HPA012763, HPA013602, CAB016249, CAB078172" Enhanced Supported Approved Vesicles NA NA Vesicles "CAB016249: AB_627402, CAB078172: AB_2665810, HPA012763: AB_2732405, HPA013602: AB_1847484" "unprognostic (2.25e-4)" "unprognostic (2.22e-1)" "unprognostic (8.45e-2)" "unprognostic (5.24e-2)" "unprognostic (7.75e-2)" "unprognostic (1.41e-2)" "unprognostic (4.64e-5)" "unprognostic (9.31e-2)" "unprognostic (7.89e-2)" "unprognostic (4.81e-2)" "unprognostic (1.30e-1)" "unprognostic (2.12e-2)" "prognostic unfavorable (3.40e-7)" "unprognostic (6.98e-2)" "unprognostic (1.64e-1)" "unprognostic (2.22e-2)" "unprognostic (4.74e-2)" 0.2 0.1 0.0 0.0 0.7 0.0 0.1 0.0 0.3 0.7 0.0 0.0 0.0 0.3 1.1 0.8 0.1 0.8 0.6 0.1 0.0 0.6 0.3 0.0 3.4 0.0 48.4 0.0 1.5 0.0 0.0 0.0 0.1 1.0 0.7 0.0 1.7 0.0 0.1 0.0 0.0 0.0 1.3 0.0 0.1 0.0 0.8 0.0 2.4 2.2 0.0 0.3 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.2 0.0 0.0 0.0 0.0 2.1 0.0 0.1 3.8 0.0 0.0 0.1 0.0 0.4 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.3 0.0 0.6 48.4 0.0 1.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 SOX21 SOX25 ENSG00000125285 "SRY-box 21" Q9Y651 13 94709622-94712399 "Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding" "Evidence at protein level" "Evidence at transcript level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "brain: 13.2;skin 1: 18.3;stomach 1: 38.7" "Group enriched" "Detected in some" 5 "Basal keratinocytes: 4.7;Suprabasal keratinocytes: 8.0" "Cancer enhanced" "Detected in many" "glioma: 12.8" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Group enriched" "Detected in some" 4 "AF22: 42.6;NTERA-2: 11.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "HPA048337, HPA064084" Approved Approved Nucleoplasm NA NA Nucleoplasm "HPA048337: AB_2732547, HPA064084: AB_2685187" "unprognostic (3.33e-1)" "prognostic favorable (7.60e-4)" "unprognostic (7.96e-2)" "prognostic favorable (8.79e-5)" "unprognostic (1.54e-2)" "unprognostic (3.87e-1)" "unprognostic (9.02e-2)" "unprognostic (2.11e-1)" "unprognostic (1.50e-1)" "unprognostic (2.90e-2)" "unprognostic (1.93e-1)" "unprognostic (6.05e-2)" "unprognostic (1.11e-1)" "unprognostic (3.51e-1)" "unprognostic (2.25e-1)" "unprognostic (1.35e-1)" 0.6 0.6 11.0 0.7 10.1 0.6 1.5 2.5 13.2 0.7 0.6 7.5 0.0 0.6 0.7 0.6 8.3 0.7 0.7 0.6 10.9 5.5 0.6 0.6 0.8 0.6 6.0 8.2 0.6 0.6 0.6 0.1 0.6 5.8 1.2 0.6 0.0 1.7 0.6 0.7 18.3 0.6 0.7 6.1 0.6 38.7 0.8 9.8 0.0 0.7 1.0 4.3 1.2 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 42.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.4 3.3 6.4 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.0 10.1 2.5 12.3 10.9 5.5 6.0 8.2 5.8 9.8 0.0 0.0 0.0 1.2 4.7 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 8.0 0.0 0.0 0.0 0.7 VCAN "CSPG2, PG-M" ENSG00000038427 Versican P13611 5 83471465-83582303 "Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins" Cataract "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Group enriched" "Detected in many" 5 "Fibroblasts: 557.1;Kupffer cells: 784.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 5 "classical monocyte: 55.5;myeloid DC: 21.3" "Group enriched" "Detected in many" 31 "dendritic cells: 21.3;monocytes: 55.5" "Cell line enhanced" "Detected in some" "AF22: 43.6;HSkMC: 29.6;hTERT-RPE1: 140.3;RPTEC TERT1: 55.4" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004726, CAB008979" Supported Approved Vesicles "Secreted to blood" NA NA 5200000 Vesicles "CAB008979: , HPA004726: AB_1080561" "unprognostic (7.90e-2)" "unprognostic (9.03e-3)" "unprognostic (7.09e-2)" "unprognostic (6.06e-3)" "unprognostic (1.87e-1)" "unprognostic (4.49e-2)" "unprognostic (1.23e-2)" "unprognostic (1.17e-2)" "prognostic unfavorable (7.59e-4)" "unprognostic (4.36e-3)" "unprognostic (2.68e-3)" "unprognostic (2.05e-1)" "prognostic unfavorable (5.17e-4)" "prognostic unfavorable (1.41e-4)" "unprognostic (1.15e-1)" "unprognostic (4.44e-2)" "unprognostic (5.30e-3)" 33.3 18.3 14.8 53.2 10.3 20.1 12.3 4.8 16.2 25.2 8.4 17.9 1.7 3.6 14.5 23.5 9.0 7.6 23.2 35.7 19.8 8.9 8.5 3.1 25.8 21.2 13.9 9.8 5.3 3.2 3.7 2.0 52.0 14.4 8.9 8.9 3.3 6.5 4.1 9.0 9.3 4.7 33.9 18.2 18.4 6.2 8.7 19.4 1.1 5.7 6.5 2.3 24.4 9.8 0.0 21.3 1.2 55.5 0.1 0.1 17.7 0.0 0.8 43.6 0.0 17.7 12.2 0.0 0.3 0.8 0.3 0.2 0.4 0.0 0.0 6.7 15.7 0.5 0.0 0.0 0.0 0.2 0.0 1.3 0.3 0.0 0.3 0.8 0.0 0.0 29.6 0.0 18.5 0.1 140.3 0.0 0.0 0.0 0.0 9.2 0.0 0.0 0.0 7.4 0.0 1.4 0.0 9.1 0.0 55.4 0.0 0.5 2.2 0.0 0.0 0.0 5.0 0.0 0.0 16.8 13.3 0.0 24.4 25.0 0.0 0.0 0.0 6.1 0.0 2.3 1.2 55.5 0.1 0.1 7.7 0.0 0.0 0.0 0.0 21.3 0.0 0.0 0.0 0.9 0.1 0.8 0.4 0.0 17.7 14.8 10.3 4.8 9.8 19.8 8.9 13.9 9.8 14.4 19.4 17.9 29.9 3.0 4.4 34.3 0.0 6.8 30.6 25.4 30.7 24.4 0.0 7.1 0.0 1.6 0.8 12.1 0.0 0.0 0.6 5.1 557.1 1.5 11.6 2.1 24.5 0.0 0.0 23.4 784.4 0.7 17.3 132.2 42.2 5.4 0.0 0.0 19.5 0.0 110.7 1.2 0.0 0.0 33.9 0.3 0.4 25.1 9.6 4.4 0.0 0.8 WNT6 ENSG00000115596 "Wnt family member 6" Q9Y6F9 2 218859821-218874233 "Predicted secreted proteins" "Wnt signaling pathway" "Developmental protein" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 23.4" "Cell type enriched" "Detected in some" 9 "Sertoli cells: 90.5" "Cancer enhanced" "Detected in many" "ovarian cancer: 8.7" "Group enriched" "Detected in many" 7 "basal ganglia: 23.4;thalamus: 7.4" "Cell type enhanced" "Detected in some" "myeloid DC: 1.1;NK-cell: 1.5" "Low lineage specificity" "Detected in many" "Cell line enriched" "Detected in some" 7 "BEWO: 28.1" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA070759 Approved "Secreted to extracellular matrix" NA NA "HPA070759: AB_2732164" "unprognostic (1.86e-2)" "unprognostic (6.03e-2)" "unprognostic (5.14e-2)" "unprognostic (2.06e-1)" "unprognostic (5.32e-2)" "unprognostic (7.34e-2)" "unprognostic (8.08e-3)" "unprognostic (4.73e-2)" "unprognostic (1.27e-2)" "unprognostic (1.19e-1)" "unprognostic (1.21e-2)" "unprognostic (2.66e-1)" "unprognostic (1.24e-3)" "unprognostic (5.26e-2)" "unprognostic (4.82e-2)" "unprognostic (1.55e-1)" "unprognostic (2.07e-1)" 2.5 3.5 0.8 1.4 23.4 0.6 15.0 0.9 2.1 4.0 5.7 0.2 1.1 1.3 2.3 2.0 3.1 2.3 2.1 4.8 0.9 0.3 1.6 0.7 0.7 1.3 2.1 0.1 2.9 1.7 0.6 1.7 9.8 1.4 4.0 0.9 4.3 1.9 2.1 2.4 2.3 2.3 2.0 2.4 6.4 2.3 3.7 7.4 0.0 0.7 0.8 1.2 1.5 11.1 0.7 1.1 0.0 0.6 1.5 0.1 0.0 0.0 0.0 0.0 0.9 0.0 0.0 28.1 0.0 0.0 0.0 0.0 2.6 0.4 0.0 3.0 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.0 0.7 0.0 0.0 0.0 0.0 0.0 2.8 0.1 0.0 0.0 4.1 1.3 0.0 0.0 3.2 0.1 3.7 0.0 0.0 2.3 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 1.1 0.7 0.0 0.0 0.0 1.5 0.0 0.7 0.0 0.0 0.8 23.4 0.9 0.9 0.9 0.3 2.1 0.1 1.4 7.4 0.0 0.0 0.5 10.5 0.5 0.8 0.4 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.2 1.6 0.0 0.0 0.0 0.0 1.5 0.8 3.2 0.0 0.0 0.7 1.6 0.0 3.1 0.0 3.4 0.0 0.0 1.7 0.0 0.0 0.8 0.0 0.0 0.4 0.0 1.8 90.5 3.3 2.1 0.3 0.1 0.6 0.0 0.0 0.9